[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 23307
1. Pereira SB, Thiel Rdo R, Riccetto C, Silva JM, Pereira LC, Herrmann V, Palma P: [Validation of the International Consultation on Incontinence Questionnaire Overactive Bladder (ICIQ-OAB) for Portuguese]. Rev Bras Ginecol Obstet; 2010 Jun;32(6):273-8
MedlinePlus Health Information. consumer health - Urinary Incontinence.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Validation of the International Consultation on Incontinence Questionnaire Overactive Bladder (ICIQ-OAB) for Portuguese].
  • [Transliterated title] Validação do International Consultation on Incontinence Questionnaire Overactive Bladder (ICIQ-OAB) para a língua portuguesa.
  • PURPOSE: To translate, culturally adapt and validate the questionnaire "International Consultation on Incontinence Questionnaire Overactive Bladder" (ICIQ-OAB) for the Portuguese Language.
  • The final version of the ICIQ-OAB was applied together with the previously translated and tested version of the International Consultation on Incontinence Questionnaire - Short Form (ICIQ-SF) in 142 male and female patients with irritative urinary symptoms.
  • CONCLUSION: The culturally adapted version of the ICIQ-OAB translated into Brazilian Portuguese presented satisfactory reliability and survey validity and was considered valid for the evaluation of irritative urinary symptoms of Brazilian patients of both genders.
  • [MeSH-major] Surveys and Questionnaires. Urinary Bladder, Overactive / diagnosis. Urinary Incontinence / diagnosis

  • Genetic Alliance. consumer health - Incontinence.
  • MedlinePlus Health Information. consumer health - Overactive Bladder.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20945012.001).
  • [ISSN] 1806-9339
  • [Journal-full-title] Revista brasileira de ginecologia e obstetrícia : revista da Federação Brasileira das Sociedades de Ginecologia e Obstetrícia
  • [ISO-abbreviation] Rev Bras Ginecol Obstet
  • [Language] por
  • [Publication-type] English Abstract; Journal Article; Validation Studies
  • [Publication-country] Brazil
  •  go-up   go-down


2. Yagnik V, Chadha A, Chaudhari S, Patel K: Inflammatory myofibroblastic tumor of the urinary bladder. Urol Ann; 2010 May;2(2):78-9

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Inflammatory myofibroblastic tumor of the urinary bladder.
  • Inflammatory myofibroblastic tumor (IMT) of bladder is an uncommon benign tumor of bladder, which is of unknown neoplastic potential, characterized by spindle cell proliferation with characteristic fibroinflammatory and pseudosarcomatous appearance.
  • Essential criteria for the diagnosis of IMT are: spindle myoepithelial cell proliferation and lymphocytic infiltrate.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20882160.001).
  • [ISSN] 0974-7834
  • [Journal-full-title] Urology annals
  • [ISO-abbreviation] Urol Ann
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] India
  • [Other-IDs] NLM/ PMC2943686
  • [Keywords] NOTNLM ; Immunohistochemical staining / inflammatory myofibroblastic tumor / spindle myoepithelial cell proliferation
  •  go-up   go-down


3. Lopez-Beltran A, Requena MJ, Cheng L, Montironi R: Pathological variants of invasive bladder cancer according to their suggested clinical significance. BJU Int; 2008 Feb;101(3):275-81
MedlinePlus Health Information. consumer health - Bladder Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pathological variants of invasive bladder cancer according to their suggested clinical significance.
  • Several pathological variants of bladder cancer, reflecting tumour heterogeneity in urothelial carcinoma, have been recently recognized.
  • It is important for both pathologists and urologists to be aware of the diverse morphological patterns in invasive bladder cancer, as they might be relevant in patient management and prognosis, mainly because they can mimic benign lesions, secondary tumours or might require a specific therapeutic approach.
  • [MeSH-major] Carcinoma / pathology. Urinary Bladder Neoplasms / pathology
  • [MeSH-minor] Diagnosis, Differential. Diagnostic Errors. Female. Humans. Male. Neoplasm Invasiveness / pathology

  • Genetic Alliance. consumer health - Bladder cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17986288.001).
  • [ISSN] 1464-410X
  • [Journal-full-title] BJU international
  • [ISO-abbreviation] BJU Int.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Number-of-references] 71
  •  go-up   go-down


Advertisement
4. Ghezala W, Saidi R, Lefi M, Saad H: [Florid glandular cystitis]. Prog Urol; 2005 Dec;15(6):1141-4
MedlinePlus Health Information. consumer health - Bladder Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Transliterated title] La cystite glandulaire floride.
  • INTRODUCTION: Florid glandular cystitis is a rare benign bladder tumour, which can simulate a malignant lesion.
  • RESULTS: This 48-year-old patient presented with terminal haematuria and right low back pain with a history of endoscopic resection of a bladder tumour.
  • Ultrasound showed a solid mass of the bladder base.
  • Intravenous urography showed bilateral uretero-caliceal dilatation, predominant on the right, with a filling defect of the bladder base.
  • CT urography showed invasion of the vesicoprostatic fat and endoscopy revealed a trigonal tumour 5 cm in diameter.
  • Improvement of the symptoms was observed on the fifth postoperative day after resection of the tumour.
  • CONCLUSION: Florid glandular cystitis is a rare benign bladder tumour.
  • The diagnosis is based on clinical examination, radiology and histological examination.
  • [MeSH-major] Cystitis. Urinary Bladder Neoplasms

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16429671.001).
  • [ISSN] 1166-7087
  • [Journal-full-title] Progrès en urologie : journal de l'Association française d'urologie et de la Société française d'urologie
  • [ISO-abbreviation] Prog. Urol.
  • [Language] fre
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] France
  •  go-up   go-down


5. Haferkamp A, Hohenfellner M: [Intravesical treatment of overactive bladder syndrome]. Urologe A; 2006 Oct;45(10):1283-8
Hazardous Substances Data Bank. OXYBUTYNIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Intravesical treatment of overactive bladder syndrome].
  • [Transliterated title] Intravesikale Therapie des Overactive-bladder-Syndroms.
  • Overactive bladder and urgency incontinence are common conditions generally treated with oral anticholinergic medication.
  • Botulinum toxin type A injections into the detrusor have been shown to increase bladder capacity and to decrease detrusor overactivity for 6 or more months.
  • Intravesical local anesthetics such as lidocaine and bupivacaine block the conduction of unmyelinated C fibers which results in an increase of functional bladder capacity.
  • Intravesical capsaicin and resiniferatoxin also affect the afferent C fiber innervation of the bladder, leading to a decrease in detrusor overactivity and also an increased bladder capacity.
  • In conclusion, intravesical therapies can provide an alternative treatment for the management of overactive bladder.
  • [MeSH-major] Administration, Intravesical. Cholinergic Antagonists / administration & dosage. Muscarinic Antagonists / administration & dosage. Urinary Bladder, Overactive / drug therapy. Urinary Incontinence / drug therapy

  • MedlinePlus Health Information. consumer health - Overactive Bladder.
  • MedlinePlus Health Information. consumer health - Urinary Incontinence.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Br J Obstet Gynaecol. 1995 Nov;102(11):929-30 [8534633.001]
  • [Cites] Urology. 2000 May;55(5A Suppl):60-4; discussion 66 [10767456.001]
  • [Cites] J Urol. 1992 Aug;148(2 Pt 2):595-7 [1640530.001]
  • [Cites] J Urol. 1989 Jun;141(6):1350-2 [2724432.001]
  • [Cites] J Urol. 2002 Nov;168(5):1897-913 [12394674.001]
  • [Cites] J Urol. 2000 Sep;164(3 Pt 1):692-7 [10953127.001]
  • [Cites] Geburtshilfe Frauenheilkd. 1991 Jan;51(1):54-7 [2026301.001]
  • [Cites] Int Braz J Urol. 2004 Jan-Feb;30(1):53-8 [15707518.001]
  • [Cites] Lancet. 1992 May 16;339(8803):1239 [1349978.001]
  • [Cites] Curr Urol Rep. 2005 Nov;6(6):429-33 [16238916.001]
  • [Cites] Neurourol Urodyn. 2005;24(3):231-6 [15747344.001]
  • [Cites] J Urol. 2003 May;169(5):1892-5 [12686868.001]
  • [Cites] Arzneimittelforschung. 1998 May;48(5):486-91 [9638316.001]
  • [Cites] BJU Int. 2005 May;95(7):1023-7 [15839924.001]
  • [Cites] J Urol. 2005 Sep;174(3):984-9 [16094019.001]
  • [Cites] Am J Obstet Gynecol. 2005 May;192(5):1735-40 [15902187.001]
  • [Cites] Eur Urol. 2004 Jul;46(1):88-93; discussion 93-4 [15183552.001]
  • [Cites] J Urol. 2005 Sep;174(3):977-82; discussion 982-3 [16094018.001]
  • [Cites] J Med Assoc Thai. 2003 Sep;86(9):861-7 [14649971.001]
  • [Cites] Urology. 2005 Jul;66(1):82-7 [15992872.001]
  • [Cites] J Urol. 2000 Aug;164(2):340-3 [10893580.001]
  • [Cites] Urology. 2000 May;55(5A Suppl):33-46; discussion 50 [10767450.001]
  • [Cites] J Obstet Gynaecol. 2006 Feb;26(2):141-3 [16483973.001]
  • [Cites] Neurourol Urodyn. 1999;18(5):447-53 [10494116.001]
  • [Cites] Geburtshilfe Frauenheilkd. 1988 Aug;48(8):562-6 [3215450.001]
  • (PMID = 16972089.001).
  • [ISSN] 0340-2592
  • [Journal-full-title] Der Urologe. Ausg. A
  • [ISO-abbreviation] Urologe A
  • [Language] ger
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Anesthetics, Local; 0 / Cholinergic Antagonists; 0 / Mandelic Acids; 0 / Muscarinic Antagonists; 0 / Neuromuscular Agents; EC 3.4.24.69 / Botulinum Toxins, Type A; K9P6MC7092 / oxybutynin
  • [Number-of-references] 26
  •  go-up   go-down


6. Mitterberger M, Pinggera GM, Neuwirt H, Maier E, Akkad T, Strasser H, Gradl J, Pallwein L, Bartsch G, Frauscher F: Three-dimensional ultrasonography of the urinary bladder: preliminary experience of assessment in patients with haematuria. BJU Int; 2007 Jan;99(1):111-6
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Three-dimensional ultrasonography of the urinary bladder: preliminary experience of assessment in patients with haematuria.
  • OBJECTIVE: To assess the value of three-dimensional (3D) vs two-dimensional (2D) ultrasonography (US) in the diagnostic evaluation of the urinary bladder in patients with haematuria.
  • Mountain View, CA, USA) and the Perspective(R) 3D technique, to assess the presence of bladder lesions, including bladder cancer, bladder wall hypertrophy with trabeculation and diverticula, mucosal bladder folds or re-growth of the prostate mimicking a bladder tumour.
  • The imaging findings were compared with cystoscopy and/or bladder biopsy.
  • RESULTS: In 21 of the 42 patients (50%) cystoscopy with bladder biopsy revealed bladder cancer.
  • Overall, 3D-US gave a correct diagnosis for 36 of 42 patients (86%).
  • All 21 bladder cancers were correctly diagnosed, and 15 (71%) of the 21 benign bladder lesions were correctly identified.
  • By contrast, 2D-US findings gave suspected bladder cancer in all patients.
  • Thus, this diagnostic technique might be useful for routine evaluation of the urinary bladder.
  • [MeSH-major] Hematuria / ultrasonography. Imaging, Three-Dimensional / instrumentation. Urinary Bladder Neoplasms / ultrasonography

  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17034493.001).
  • [ISSN] 1464-4096
  • [Journal-full-title] BJU international
  • [ISO-abbreviation] BJU Int.
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] England
  •  go-up   go-down


7. Schmidt A, Sommer F, Reiner M, Klotz T, Engelmann U, Addicks K, Bloch W: Differential endostatin binding to bladder, prostate and kidney tumour vessels. BJU Int; 2005 Jan;95(1):174-9
MedlinePlus Health Information. consumer health - Prostate Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Differential endostatin binding to bladder, prostate and kidney tumour vessels.
  • OBJECTIVES: To define the anti-angiogenic mechanism and causes of the heterogeneous influence of endostatin, one of a group of matrix-derived inhibitors of tumour angiogenesis of increasing significance in tumour treatment, on various tissue types.
  • MATERIALS AND METHODS: Variations in the binding behaviour of endostatin with vessels were assessed in different tumours (bladder, prostate and kidney) and compared with benign tissue vessels.
  • RESULTS: There were significant differences in the number of vessels showing endostatin binding among benign and malignant bladder, prostate and kidney tissues.
  • While there was distinct endostatin binding on a mean (sd) of 94.2 (3.0)% bladder and 73.8 (19.5)% prostate tumour vessels, there was less binding, at 11.32 (3.9)%, on kidney tumour vessels.
  • There was less binding to vessels of benign bladder, prostate and kidney tissue, at 2.0 (1.5), 1.7 (1.7) and 1.5 (1.7)%, respectively.
  • CONCLUSION: Endostatin binds more to all tumour tissues than to benign tissue, but the degree of binding in malignant kidney tissue was significantly less than that in malignant prostate and bladder tissues.
  • These divergent vascular endostatin-binding patterns could be responsible for a tumour type-dependent anti-angiogenic effect attributable to endostatin.
  • Such selective behaviour would have therapeutic consequences for future anti-angiogenic therapy, in which different kinds of tumours could be further classified into those responding to endostatin or not.
  • [MeSH-major] Endostatins / metabolism. Kidney Neoplasms / metabolism. Prostatic Neoplasms / metabolism. Urinary Bladder Neoplasms / metabolism
  • [MeSH-minor] Aged. Blotting, Western. Humans. Kidney / blood supply. Kidney / metabolism. Male. Prostate / blood supply. Prostate / metabolism. Urinary Bladder / blood supply. Urinary Bladder / metabolism

  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15638918.001).
  • [ISSN] 1464-4096
  • [Journal-full-title] BJU international
  • [ISO-abbreviation] BJU Int.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Endostatins
  •  go-up   go-down


8. Herr H, Donat M, Dalbagni G, Taylor J: Narrow-band imaging cystoscopy to evaluate bladder tumours--individual surgeon variability. BJU Int; 2010 Jul;106(1):53-5
MedlinePlus Health Information. consumer health - Bladder Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Narrow-band imaging cystoscopy to evaluate bladder tumours--individual surgeon variability.
  • STUDY TYPE: Diagnosis (exploratory cohort) Level of Evidence 2b.
  • OBJECTIVE: To assess individual urologist variability using narrow-band imaging (NBI) cystoscopy to evaluate bladder tumours.
  • PATIENTS AND METHODS: In all, 50 patients underwent white-light and NBI cystoscopy to evaluate for recurrent bladder tumours.
  • Endoscopic images in each patient were independently viewed by four urologists assessing presence or absence of tumour.
  • RESULTS: In all, 26 patients had recurrent tumour and 24 had benign histology.
  • There were no significant differences among urologists detecting recurrent tumour or in determining final pathology.
  • CONCLUSIONS: There does not appear to be a 'learning curve' for adapting to NBI-surveillance cystoscopy in patients with bladder cancer.
  • [MeSH-major] Cystoscopy / methods. Image Enhancement / methods. Neoplasm Recurrence, Local / diagnosis. Urinary Bladder Neoplasms / diagnosis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] BJU Int. 2008 Nov;102(9):1111-4 [18778359.001]
  • [Cites] BJU Int. 2008 Mar;101(6):702-5; discussion 705-6 [18005206.001]
  • (PMID = 20002669.001).
  • [ISSN] 1464-410X
  • [Journal-full-title] BJU international
  • [ISO-abbreviation] BJU Int.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / T32 CA082088; United States / NCI NIH HHS / CA / T32 CA082088-12
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ NIHMS297487; NLM/ PMC3137239
  •  go-up   go-down


9. Schwalenberg T, Neuhaus J, Horn LC, Alexander H, Zimmermann G, Ho Thi P, Mallock T, Stolzenburg JU: [New insights in the differential diagnosis of bladder pain syndrome]. Aktuelle Urol; 2010 Mar;41(2):107-18
MedlinePlus Health Information. consumer health - Interstitial Cystitis.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [New insights in the differential diagnosis of bladder pain syndrome].
  • [Transliterated title] Neue Erkenntnisse zur Differenzialdiagnostik des Bladder-Pain-Syndroms.
  • The diagnosis of bladder pain syndrome/interstitial cystitis (BPS/IC) is challenging, since pathogenetic mechanisms and the definition of clinical relevant parameters are still under lively discussion.
  • The criteria recently proposed by the European Society for the Study of Interstitial Cystitis (ESSIC) define a collective of patients based on the cardinal symptom of bladder pain which is heterogeneous, and therefore cannot receive standardised consistent therapy.
  • Thus an extended diagnosis based on molecular markers seems to be indicated to render individual pharmacotherapy possible, and to contribute to elucidation of BPS/IC pathogenesis.
  • For this purpose we feel the vital need for taking a bladder biopsy.
  • The diagnosis of BPS/IC should rely on 3 "columns":.
  • Since a significant contribution of the 3 functional units of the bladder to the pathophysiology is most evident, the examinations should ideally include urothelium, lamina propria, and detrusor musculature.
  • [MeSH-major] Cystitis, Interstitial / diagnosis
  • [MeSH-minor] Biopsy. Capillaries / pathology. Capillaries / physiopathology. Chorionic Gonadotropin, beta Subunit, Human / genetics. Cystoscopy. Diagnosis, Differential. Gene Expression / physiology. Humans. Mast Cells / pathology. Mast Cells / physiology. Mucous Membrane / pathology. Mucous Membrane / physiopathology. Nerve Fibers / pathology. Nerve Fibers / physiology. Practice Guidelines as Topic. Receptors, G-Protein-Coupled / genetics. Risk Factors. Urinary Bladder / pathology. Urinary Bladder / physiopathology. Urinary Bladder, Overactive / classification. Urinary Bladder, Overactive / pathology. Urinary Bladder, Overactive / physiopathology. Urothelium / pathology. Urothelium / physiopathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Georg Thieme Verlag Stuttgart New York.
  • (PMID = 20309783.001).
  • [ISSN] 1438-8820
  • [Journal-full-title] Aktuelle Urologie
  • [ISO-abbreviation] Aktuelle Urol
  • [Language] ger
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Chorionic Gonadotropin, beta Subunit, Human; 0 / Receptors, G-Protein-Coupled
  • [Number-of-references] 52
  •  go-up   go-down


10. Bensalah K, Patard JJ: [Management of T1G3 tumours of the bladder]. Ann Urol (Paris); 2006 Apr;40(2):93-100
MedlinePlus Health Information. consumer health - Bladder Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Management of T1G3 tumours of the bladder].
  • [Transliterated title] Prise en charge des tumeurs de vessie T1G3 management of T1G3 tumours of the bladder.
  • T1G3 tumours are the most aggressive superficial tumours of the bladder, with a high risk of recurrence and progression.
  • Complete endoscopic resection of the tumour is the first diagnostic and therapeutic step in T1G3 management.
  • A second resection should be done at 1 month to avoid residual tumour and misdiagnosis of a muscle infiltrative cancer.
  • As a result of treatment by instillations of Calmette and Guérin bacillus following endoscopic resection, a 5-year survival rate of 80% has been reported, with 50 to 60% of bladder preservation.
  • BCG is the only conservative treatment that has proven effectiveness on both tumour recurrence and progression.
  • Radical cystectomy can be chosen as first line treatment in patients with particularly aggressive tumours.
  • [MeSH-major] Urinary Bladder Neoplasms / diagnosis. Urinary Bladder Neoplasms / therapy
  • [MeSH-minor] Adjuvants, Immunologic / therapeutic use. BCG Vaccine / therapeutic use. Humans. Neoplasm Staging

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16709007.001).
  • [ISSN] 0003-4401
  • [Journal-full-title] Annales d'urologie
  • [ISO-abbreviation] Ann Urol (Paris)
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] France
  • [Chemical-registry-number] 0 / Adjuvants, Immunologic; 0 / BCG Vaccine
  • [Number-of-references] 58
  •  go-up   go-down


11. Gonzalo Rodríguez V, Sanz Justo L, de Miguel Santamaría I, Martínez de Iturrate J, Fernández del Busto E: [The use of NMP22 Bladder-Chek for the diagnosis and follow-up bladder cancer]. Arch Esp Urol; 2008 Apr;61(3):377-84
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [The use of NMP22 Bladder-Chek for the diagnosis and follow-up bladder cancer].
  • [Transliterated title] Empleo del NMP22 Bladder-Chek en el diagnóstico y seguimiento del cáncer de vejiga.
  • OBJECTIVES: The goal of this work is to evaluate the usefulness of NMP22 BladderChek in the diagnosis and follow-up of bladder cancer, comparing it with cystoscopy and urine cytology.
  • METHODS: Group 1: 109 asymptomatic patients on follow up for bladder cancer underwent cystoscopy, cytology and NMP22 BladderChek.
  • RESULTS: Group 1: 9 patients had tumor relapse.
  • Group 2: 12 patients had bladder cancer.
  • CONCLUSIONS: The low sensitivity of NMP22 Bladder-Chek invalidates it as alternative method to cystoscopy in the follow-up of bladder cancer.
  • But it can be recommended for screening in patients without history of bladder cancer but with an increased risk (smokers, patients with dysuria and hematuria).
  • [MeSH-major] Biomarkers, Tumor / urine. Neoplasm Recurrence, Local / diagnosis. Nuclear Proteins / urine. Urinary Bladder Neoplasms / diagnosis
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Carcinoma, Transitional Cell / pathology. Cystoscopy. Cytodiagnosis. Female. Hematuria / etiology. Hematuria / urine. Humans. Male. Middle Aged. Neoplasm Staging. Predictive Value of Tests. Reagent Strips

  • Genetic Alliance. consumer health - Bladder cancer.
  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18581675.001).
  • [ISSN] 0004-0614
  • [Journal-full-title] Archivos españoles de urología
  • [ISO-abbreviation] Arch. Esp. Urol.
  • [Language] spa
  • [Publication-type] Comparative Study; English Abstract; Evaluation Studies; Journal Article
  • [Publication-country] Spain
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Nuclear Proteins; 0 / Reagent Strips; 0 / nuclear matrix protein 22
  •  go-up   go-down


12. Aguilera Tubet C, Gutiérrez Baños JL, Antolín Juárez F, Rebollo Rodrigo MH, Portillo Martín JA, Ruiz Izquierdo F, Ballestero Diego R, Martín García B: [Comparative study between cystoscopy, urinary cytology, NMP-22 and a new method, bladder chek, in the follow-up of superficial bladder cell carcinoma]. Actas Urol Esp; 2005 Mar;29(3):252-6
MedlinePlus Health Information. consumer health - Urine and Urination.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Comparative study between cystoscopy, urinary cytology, NMP-22 and a new method, bladder chek, in the follow-up of superficial bladder cell carcinoma].
  • [Transliterated title] Estudio comparativo entre cistoscopia, citología urinaria, NMP-22 y un nuevo método, bladder chek, en el seguimiento del cáncer vesical superficial.
  • OBJECTIVE: The goal of this work tries to evaluate the utility of the qualitative determination of NMP-22 in the evaluation of the superficial bladder carcinoma in asymptomatic patients, comparing it with its quantitative determination, the cytology and the cystoscopy.
  • MATERIALS AND METHODS: A simple of urine just voided was taken in 88 asymptomatic patient follow-up for superficial bladder cell carcinoma.
  • This dose was distributed in 3 parts, for performed cytology, for determination of NMP-22, and 4 drops of the third part are added to device bladder chek.
  • Later, we performed cystoscopy and transurethral resection in patients with a suspicion of bladder cancer.
  • RESULTS: 26 patients had tumor relapse and 62 patients were free of disease.
  • The sensitivity for the bladder chek was of 28%, 34.62% for NMP-22, 34.62% for cytology and 100% for cystoscopy.
  • The sensitivity by degree was 25 in G1, 28.57 in G2 and 50 in G3 for Bladder chek; 29.41, 42.86 and 50 for NMP-22; 23.53, 71.43 and 0 for cytology.
  • The sensitivity by stages was 27.7 in Ta-1 and 50 in T2 for Bladder chek; 34.78 and 50 for NMP-22; 39.13 and 0 for the cytology.
  • CONCLUSIONS: The low sensitivity of bladder chek invalidates it like alternative method to the cystoscopy in the follow-up of the superficial asymptomatic bladder cell carcinoma.
  • [MeSH-major] Carcinoma, Transitional Cell / diagnosis. Cystoscopy. Immunologic Tests. Nuclear Proteins / analysis. Urinary Bladder Neoplasms / diagnosis. Urine / cytology

  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15945249.001).
  • [ISSN] 0210-4806
  • [Journal-full-title] Actas urologicas españolas
  • [ISO-abbreviation] Actas Urol Esp
  • [Language] spa
  • [Publication-type] Comparative Study; English Abstract; Journal Article
  • [Publication-country] Spain
  • [Chemical-registry-number] 0 / Nuclear Proteins; 0 / nuclear matrix protein 22
  •  go-up   go-down


13. Gaunez N, Larré S, Pirès C, Doré B, Wei J, Pfister C, Irani J: [French translation and linguistic validation of the questionnaire Bladder Cancer Index (BCI)]. Prog Urol; 2010 May;22(6):350-3
MedlinePlus Health Information. consumer health - Bladder Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [French translation and linguistic validation of the questionnaire Bladder Cancer Index (BCI)].
  • [Transliterated title] Traduction en langue française et validation linguistique de l'auto-questionnaire Bladder Cancer Index évaluant la qualité de vie dans les tumeurs de vessie.
  • OBJECTIVE: Translation and linguistic validation of the French version of Bladder Cancer Index (BCI).
  • MATERIAL AND METHODS: A double-back translation of the original Bladder Cancer Index was performed.
  • Finally, a pilot study followed by an interview was carried out among one woman and five men having bladder cancer.
  • The impact of various bladder cancer treatment on quality of life could hence be assessed and compared.
  • [MeSH-major] Surveys and Questionnaires. Urinary Bladder Neoplasms

  • Genetic Alliance. consumer health - Bladder cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2011 Elsevier Masson SAS. All rights reserved.
  • (PMID = 22541905.001).
  • [ISSN] 1166-7087
  • [Journal-full-title] Progrès en urologie : journal de l'Association française d'urologie et de la Société française d'urologie
  • [ISO-abbreviation] Prog. Urol.
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article; Validation Studies
  • [Publication-country] France
  •  go-up   go-down


14. Thiel DD, Williams BF, Krishna M, Leroy TJ, Igel TC: Robot-assisted laparoscopic excision of bladder wall leiomyoma. J Endourol; 2009 Apr;23(4):579-82; discussion 582
MedlinePlus Health Information. consumer health - Bladder Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Robot-assisted laparoscopic excision of bladder wall leiomyoma.
  • Leiomyoma is the most frequent nonepithelial benign tumor of the bladder, and only about 170 cases have been reported in the literature.
  • Most bladder wall leiomyomas are found incidentally and can be clinically followed if imaging and biopsy findings are consistent with the diagnosis.
  • Resection is usually performed for symptomatic or enlarging masses and is indicated if the diagnosis is in question.
  • We demonstrate imaging characteristics, port placement, operative technique, and surgical pathologic findings of the first reported case of robot-assisted laparoscopic resection of a bladder wall leiomyoma.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19335142.001).
  • [ISSN] 1557-900X
  • [Journal-full-title] Journal of endourology
  • [ISO-abbreviation] J. Endourol.
  • [Language] ENG
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


15. Wang CL, Tsai EM, Liu CM, Wu CH, Long CY: Incidental finding of a benign bladder tumor during the tension-free vaginal tape procedure. Gynecol Obstet Invest; 2007;63(1):28-30
MedlinePlus Health Information. consumer health - Pelvic Support Problems.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Incidental finding of a benign bladder tumor during the tension-free vaginal tape procedure.
  • However, concomitant resection of a bladder tumor during the TVT procedure is rare.
  • A bladder tumor located in the trigone was found incidentally during cystoscopy.
  • Concomitant resection of the bladder tumor was performed following the TVT procedure.
  • The surgical result of our patient suggests that concomitant resection of a benign intravesical pathology with TVT procedure is safe and effective.
  • [MeSH-major] Cystoscopy. Urinary Bladder Neoplasms / diagnosis. Urinary Bladder Neoplasms / surgery. Urinary Incontinence, Stress / surgery

  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16864984.001).
  • [ISSN] 0378-7346
  • [Journal-full-title] Gynecologic and obstetric investigation
  • [ISO-abbreviation] Gynecol. Obstet. Invest.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Switzerland
  • [Number-of-references] 13
  •  go-up   go-down


16. Njim L, Dhouibi A, Binous Y, Touil N, Zakhama A, Moussa A: [Pseudosarcomatous myofibroblastic proliferation of the bladder]. Prog Urol; 2010 Apr;20(4):307-10
MedlinePlus Health Information. consumer health - Bladder Diseases.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Pseudosarcomatous myofibroblastic proliferation of the bladder].
  • [Transliterated title] Prolifération myofibroblastique pseudosarcomateuse de la vessie.
  • Myofibroblastic proliferations of the bladder in adults are unusual lesions with a benign course.
  • Histologically, similar lesions have been reported in the literature using different names, such as inflammatory pseudotumour, pseudosarcomatous fibromyxoid tumour, nodular fasciitis, postoperative spindle cell nodule... Recently, some authors proposed that these lesions are similar enough to be considered the same entity, designated as "pseudosarcomatous myofibroblastic proliferation" and insisted on the necessity to distinguish them from the inflammatory myofibroblastic tumour of the childhood.
  • The latter, recently recognized as tumour, has a malignant potential and is capable of giving metastases.
  • We describe the case of a 17-year-old man who presented a vesical mass.
  • We discuss, through a literature review, the relationship of this lesion with inflammatory myofibroblastic tumour and its main differential diagnoses.
  • [MeSH-major] Urinary Bladder Diseases / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2009 Elsevier Masson SAS. All rights reserved.
  • (PMID = 20380994.001).
  • [ISSN] 1166-7087
  • [Journal-full-title] Progrès en urologie : journal de l'Association française d'urologie et de la Société française d'urologie
  • [ISO-abbreviation] Prog. Urol.
  • [Language] fre
  • [Publication-type] Case Reports; English Abstract; Journal Article; Review
  • [Publication-country] France
  • [Number-of-references] 5
  •  go-up   go-down


17. Farouk K, Gondal M, Ahmad A, Bano U, Khan A: Leiomyoma of the urinary bladder with bladder stone. J Coll Physicians Surg Pak; 2008 Sep;18(9):592-4

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Leiomyoma of the urinary bladder with bladder stone.
  • Leiomyoma of the urinary bladder is a rare benign mesenchymal tumour.
  • We describe here a case of leiomyoma of the urinary bladder in a 65-year-old gentleman who presented with haematuria, passage of clots and combined obstructive and irritative urinary symptoms.
  • The investigations revealed a vesical calculus and a mass on the left lateral wall of the urinary bladder.
  • Cystolitholapaxy and transurethral resection of the tumour was performed.
  • Histopathological report of the resected tumour revealed a leiomyoma of the urinary bladder.
  • So far, a leiomyoma of the urinary bladder and a concomitant vesical calculus have not been described in literature.
  • [MeSH-major] Leiomyoma / diagnosis. Urinary Bladder / pathology. Urinary Bladder Calculi / diagnosis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18803905.001).
  • [ISSN] 1022-386X
  • [Journal-full-title] Journal of the College of Physicians and Surgeons--Pakistan : JCPSP
  • [ISO-abbreviation] J Coll Physicians Surg Pak
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Pakistan
  •  go-up   go-down


18. Lopez-Beltran A: Bladder cancer: clinical and pathological profile. Scand J Urol Nephrol Suppl; 2008 Sep;(218):95-109
MedlinePlus Health Information. consumer health - Bladder Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Bladder cancer: clinical and pathological profile.
  • Bladder tumours represent a heterogeneous group of cancers.
  • The natural history of these bladder cancers is that of recurrence of disease and progression to higher grade and stage disease.
  • Furthermore, recurrence and progression rates of superficial bladder cancer vary according to several tumour characteristics, mainly tumour grade and stage.
  • The most recent World Health Organization (WHO) classification of tumours of the urinary system includes urothelial flat lesions: flat hyperplasia, dysplasia and carcinoma in situ.
  • The papillary lesions are broadly subdivided into benign (papilloma and inverted papilloma), papillary urothelial neoplasia of low malignant potential (PUNLMP) and non-invasive papillary carcinoma (low or high grade).
  • Whether PUNLMP remains a clinically useful category, or whether this category should be expanded to include all low-grade, stage Ta lesions (PUNLMP and low-grade papillary carcinoma) as a wider category of less aggressive tumours not labelled as cancer, needs to be discussed in the near future.
  • This article summarizes the recent literature concerning important issues in the pathology and the clinical management of patients with bladder urothelial carcinoma.
  • Emphasis is placed on clinical presentation, the significance of haematuria, macroscopic appearance (papillary, solid or mixed, single or multiple) and synchronous or metachronous presentation (field disease vs monoclonal disease with seeding), classification and microscopic variations of bladder cancer with clinical significance, TNM distribution and the pathological grading according to the 2004 WHO proposal.
  • [MeSH-major] Urinary Bladder Neoplasms / pathology
  • [MeSH-minor] Disease Progression. Humans. Hyperplasia. Neoplasm Staging. Urothelium / pathology

  • Genetic Alliance. consumer health - Bladder cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18815924.001).
  • [ISSN] 0300-8886
  • [Journal-full-title] Scandinavian journal of urology and nephrology. Supplementum
  • [ISO-abbreviation] Scand J Urol Nephrol Suppl
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Sweden
  • [Number-of-references] 100
  •  go-up   go-down


19. Mamoon N, Iqbal MA, Jamal S, Luqman M: Urothelial neoplasia of the urinary bladder--comparison of interobserver variability for WHO Classification 1972 with WHO/ISUP Consensus Classification 1998. J Ayub Med Coll Abbottabad; 2006 Apr-Jun;18(2):4-8
MedlinePlus Health Information. consumer health - Bladder Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Urothelial neoplasia of the urinary bladder--comparison of interobserver variability for WHO Classification 1972 with WHO/ISUP Consensus Classification 1998.
  • BACKGROUND: Classification of urothelial bladder tumours is an important factor in the treatment and prognosis of these lesions.
  • The objective of this study was to classify urothelial neoplasms of the urinary bladder using the latest WHO/ISUP Consensus Classification 1998 and WHO Classification 1972 and compare the two regarding interobserver variability.
  • METHODS: This study included 100 consecutive biopsy specimens of urothelial neoplasms of the urinary bladder diagnosed at the department of Histopathology, Armed Forces Institute of Pathology, Rawalpindi.
  • The tumour categories for WHO classification 1972; papilloma, and transitional cell carcinoma (TCC) grades I, II and III were compared with the WHO/ISUP Consensus Classification entities of papilloma, papillary neoplasm of low malignant potential, low grade and high grade papillary carcinomas.
  • RESULTS: There was agreement on 80 tumours between the two groups of histopathologists when using WHO classification 1972 while there was agreement on 95 tumours using WHO/ISUP consensus classification.
  • Kappa values were less for benign and borderline lesions using both systems.
  • CONCLUSIONS: WHO/ISUP Consensus Classification 1998 showed less interobserver variability than WHO Classification 1972 in the evaluation of bladder tumours.
  • There was less agreement on the benign and borderline lesions using both the classifications.
  • [MeSH-major] Urinary Bladder Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16977804.001).
  • [ISSN] 1025-9589
  • [Journal-full-title] Journal of Ayub Medical College, Abbottabad : JAMC
  • [ISO-abbreviation] J Ayub Med Coll Abbottabad
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Pakistan
  •  go-up   go-down


20. Shanks JH, Iczkowski KA: Spindle cell lesions of the bladder and urinary tract. Histopathology; 2009 Nov;55(5):491-504
MedlinePlus Health Information. consumer health - Bladder Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Spindle cell lesions of the bladder and urinary tract.
  • Spindle cell lesions of the urinary tract encompass a variety of benign and malignant tumours as well as a group of lesions of controversial nomenclature that is the subject of ongoing debate.
  • This review focuses on our current and evolving understanding of the lesion variably referred to as inflammatory myofibroblastic tumour, pseudosarcomatous myofibroblastic proliferation or inflammatory pseudotumour and the main differential diagnoses of sarcomatoid carcinoma and sarcoma.
  • Other spindle cell lesions of the bladder are described.
  • [MeSH-major] Urinary Bladder Neoplasms / pathology. Urinary Tract / pathology
  • [MeSH-minor] Diagnosis, Differential. Humans. Sarcoma / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19912355.001).
  • [ISSN] 1365-2559
  • [Journal-full-title] Histopathology
  • [ISO-abbreviation] Histopathology
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Number-of-references] 120
  •  go-up   go-down


21. Jalpota Y, Tewari V, Madan R: Recurrent nephrogenic adenoma of urinary bladder in a renal allograft recipient--a case report. Indian J Pathol Microbiol; 2006 Apr;49(2):261-3
MedlinePlus Health Information. consumer health - Kidney Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Recurrent nephrogenic adenoma of urinary bladder in a renal allograft recipient--a case report.
  • Nephrogenic adenoma is a rare benign tumour-like lesion within the urothelial mucosa of the urinary tract.
  • It may be an incidental finding in bladder of a patient presenting with haematuria, dysuria and bladder growth after renal allograft transplant.
  • Clinically it mimics bladder neoplasm.
  • Definite diagnosis is established by histological examination of tumor.
  • Though it attains an extensive spread in bladder mucosa and has a high tendency to recur, the clinical course is benign.
  • [MeSH-major] Adenoma / pathology. Kidney Neoplasms. Neoplasm Recurrence, Local / pathology. Urinary Bladder Neoplasms / pathology
  • [MeSH-minor] Adult. Diagnosis, Differential. Humans

  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16933732.001).
  • [ISSN] 0377-4929
  • [Journal-full-title] Indian journal of pathology & microbiology
  • [ISO-abbreviation] Indian J Pathol Microbiol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] India
  •  go-up   go-down


22. Paul A, Buisson P, Ricard J, Cordonnier C, Canarelli JP: [Inflammatory pseudotumour of the bladder in children: report of a new case and review of the literature]. Prog Urol; 2007 Sep;17(5):1005-7
MedlinePlus Health Information. consumer health - Bladder Diseases.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Inflammatory pseudotumour of the bladder in children: report of a new case and review of the literature].
  • [Transliterated title] Pseudo tumeur inflammatoire de vessie chez l'enfant: a propos d'une nouvelle observation et revue de la littérature.
  • Bladder tumour is rare in children and usually corresponds to embryonic rhabdomyosarcoma.
  • However one of the differential diagnoses is inflammatory pseudotumour of the bladder which is a benign lesion with a good prognosis.
  • The authors report the case of a 3-year-old boy who presented with macroscopic haematuria related to a lesion of the anterior bladder wall.
  • Histological examination of the partial cystectomy specimen demonstrated inflammatory pseudotumour of the bladder that was confirmed by a review examination.
  • [MeSH-major] Cysts / pathology. Inflammation / pathology. Urinary Bladder Diseases / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17969809.001).
  • [ISSN] 1166-7087
  • [Journal-full-title] Progrès en urologie : journal de l'Association française d'urologie et de la Société française d'urologie
  • [ISO-abbreviation] Prog. Urol.
  • [Language] fre
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] France
  •  go-up   go-down


23. Gaisa NT, Henkel C, Knüchel R: Tumour node metastasis staging of bladder cancer: prognosis versus pitfalls. Curr Opin Urol; 2010 Sep;20(5):398-403
MedlinePlus Health Information. consumer health - Bladder Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Tumour node metastasis staging of bladder cancer: prognosis versus pitfalls.
  • PURPOSE OF REVIEW: The WHO classification of urothelial cancer in 2004 has made changes based on the insights of molecular genetics, indicating bladder cancer with entities that are genetically stable versus those that are genetically instable.
  • Clinical studies based on solid histological diagnosis are as necessary as the definition of more molecular features of bladder cancer.
  • RECENT FINDINGS: Solid histological diagnosis includes sufficient clinical information and adequate tissue processing.
  • This combined with molecular data will lead to a more clear-cut distinction between benign and malignant and possibly to another change in terminology with higher concordance to other epithelial tumours.
  • Whereas the identification of FGFR3 mutations has led to a better distinction of at least two pathways of urothelial carcinogenesis, additional multiparametric approaches may help improve the still inadequate search for urine and blood markers indicative of bladder cancer and/or its progression.
  • SUMMARY: Recent data mainly support the concept of the WHO 2004 classification of bladder cancer.
  • We are optimistic that an even more clear-cut distinction between benign recurring, nonprogressing tumours and more aggressive tumours will enable us to focus and limit chemotherapy.
  • [MeSH-major] Lymph Nodes / pathology. Neoplasm Staging. Urinary Bladder Neoplasms / pathology
  • [MeSH-minor] Humans. Lymphatic Metastasis. Molecular Diagnostic Techniques. Neoplasm Invasiveness. Predictive Value of Tests. Prognosis. Reproducibility of Results

  • Genetic Alliance. consumer health - Bladder cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20625299.001).
  • [ISSN] 1473-6586
  • [Journal-full-title] Current opinion in urology
  • [ISO-abbreviation] Curr Opin Urol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  •  go-up   go-down


24. Jarmalaite S, Jankevicius F, Kurgonaite K, Suziedelis K, Mutanen P, Husgafvel-Pursiainen K: Promoter hypermethylation in tumour suppressor genes shows association with stage, grade and invasiveness of bladder cancer. Oncology; 2008;75(3-4):145-51
MedlinePlus Health Information. consumer health - Bladder Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Promoter hypermethylation in tumour suppressor genes shows association with stage, grade and invasiveness of bladder cancer.
  • AIMS: Superficial bladder cancer is a highly recurrent disease, with progression to muscle invasiveness occurring in 15-30% of cases.
  • Promoter hypermethylation in a panel of tumour suppressor genes involved in cell cycle control, apoptosis and DNA repair was analyzed in superficial bladder tumours in order to evaluate the suitability of epigenetic biomarkers for an earlier prediction of the aggressive course of the disease.
  • METHOD: Promoter hypermethylation in p16, RARbeta, RASSF1A, DAPK, and MGMT genes was analyzed in 58 cases with superficial bladder cancer and 2 cases with benign urological disease using methylation-specific PCR.
  • RESULTS: Promoter hypermethylation was frequently detected in RARbeta, RASSF1A and DAPK genes, and 62% of bladder tumours exhibited hypermethylation in at least one gene.
  • The overall frequency of hypermethylation and the number of genes involved increased with tumour stage, grade and muscle invasiveness.
  • Aberrant methylation of RASSF1A and RARbetawas predominant (p < 0.05) in muscle-invasive tumours and high-grade tumours, respectively.
  • CONCLUSION: The results suggest analysis of promoter hypermethylation as a valuable biomarker for prognosis of the aggressive course of disease in bladder cancer.
  • [MeSH-major] DNA Methylation. Genes, Tumor Suppressor. Promoter Regions, Genetic / genetics. Urinary Bladder Neoplasms / genetics. Urinary Bladder Neoplasms / pathology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Carcinoma, Transitional Cell / genetics. Carcinoma, Transitional Cell / pathology. DNA, Neoplasm / genetics. Female. Humans. Male. Middle Aged. Muscle Neoplasms / genetics. Muscle Neoplasms / pathology. Neoplasm Invasiveness. Neoplasm Staging. Polymerase Chain Reaction. Prognosis

  • Genetic Alliance. consumer health - Bladder cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2008 S. Karger AG, Basel.
  • (PMID = 18824877.001).
  • [ISSN] 1423-0232
  • [Journal-full-title] Oncology
  • [ISO-abbreviation] Oncology
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / DNA, Neoplasm
  •  go-up   go-down


25. Sun Y, He DL, Ma Q, Wan XY, Zhu GD, Li L, Luo Y, He H, Yang L: Comparison of seven screening methods in the diagnosis of bladder cancer. Chin Med J (Engl); 2006 Nov 5;119(21):1763-71
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Comparison of seven screening methods in the diagnosis of bladder cancer.
  • BACKGROUND: We compared the validity (evaluated by sensitivity and specificity), reliability (evaluated by reproducibility) and yield (evaluated by predictive value, examining complexity and cost) of individual and combined tests for bladder tumour antigen stat (BTAstat), nuclear matrix protein 22 (NMP22), hyaluronic acid (HA), survivin, CD44v6, vascular endothelial growth factor (VEGF), and voided urine cytology (VUC) in detecting bladder cancer.
  • And at the same time we evaluated the clinical value of these seven detecting methods in the diagnosis of bladder cancer.
  • METHODS: The six markers and VUC were detected in the urine of cancer group (151 patients with bladder cancer) and two control groups (50 patients with benign urological diseases and 50 healthy controls).
  • RESULTS: There was a significant difference between bladder cancer group and the two control groups.
  • CONCLUSIONS: All the markers have obvious clinical value in diagnosis of bladder cancer.
  • [MeSH-major] Biomarkers, Tumor / analysis. Urinary Bladder Neoplasms / diagnosis
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Antigens, CD44 / analysis. Antigens, Neoplasm / analysis. Female. Glycoproteins / analysis. Humans. Hyaluronic Acid / analysis. Inhibitor of Apoptosis Proteins. Male. Microtubule-Associated Proteins / analysis. Middle Aged. Neoplasm Proteins / analysis. Neoplasm Staging. Nuclear Proteins / analysis. Sensitivity and Specificity. Vascular Endothelial Growth Factor A / analysis

  • Genetic Alliance. consumer health - Bladder cancer.
  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • Hazardous Substances Data Bank. HYALURONIC ACID .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17097029.001).
  • [ISSN] 0366-6999
  • [Journal-full-title] Chinese medical journal
  • [ISO-abbreviation] Chin. Med. J.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Antigens, CD44; 0 / Antigens, Neoplasm; 0 / BIRC5 protein, human; 0 / Biomarkers, Tumor; 0 / CD44v6 antigen; 0 / Glycoproteins; 0 / Inhibitor of Apoptosis Proteins; 0 / Microtubule-Associated Proteins; 0 / Neoplasm Proteins; 0 / Nuclear Proteins; 0 / Vascular Endothelial Growth Factor A; 0 / nuclear matrix protein 22; 9004-61-9 / Hyaluronic Acid
  •  go-up   go-down


26. Eissa S, Ali HS, Al Tonsi AH, Zaglol A, El Ahmady O: HER2/neu expression in bladder cancer: relationship to cell cycle kinetics. Clin Biochem; 2005 Feb;38(2):142-8
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] HER2/neu expression in bladder cancer: relationship to cell cycle kinetics.
  • BACKGROUND AND OBJECTIVES: The incidence of overexpression of HER2/neu in bladder cancer is one of the highest among all human malignancies tested; such overexpression is thought to play a role in the aberrant proliferation of cancer cells.
  • This study was conducted to evaluate the quantitative assessment of HER2/neu expression by enzyme immunoassay (EIA) and its prognostic significance in differentiating between high and low proliferating tumors.
  • PATIENTS AND METHODS: Tissue samples were collected from 35 patients with benign bladder lesions, 28 with bilharzial bladder cancer, and 25 with nonbilharzial bladder cancer.
  • Twenty normal samples were obtained from normal safety margin areas in nonbilharzial bladder cancer patients.
  • RESULTS: HER2/neu was found to be significantly overexpressed in the malignant group compared to the benign and normal groups (P < 0.001) and no significant difference was found between the bilharzial and nonbilharzial cancer groups or between the transitional and squamous cell carcinoma groups.
  • No significant correlation was found between HER2/neu and stage or grade while it was significantly associated with lymph node status of the tumour (P = 0.02).
  • The quantitative assessment of HER2/neu expression in malignant tumors aided by other proliferation markers such as SPF, DI, and ploidy could be useful in selecting patients for more aggressive treatment or for predicting outcome.
  • [MeSH-major] Cell Cycle. Gene Expression Regulation, Neoplastic. Receptor, ErbB-2 / analysis. Urinary Bladder Neoplasms / pathology

  • Genetic Alliance. consumer health - Bladder cancer.
  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15642276.001).
  • [ISSN] 0009-9120
  • [Journal-full-title] Clinical biochemistry
  • [ISO-abbreviation] Clin. Biochem.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 9007-49-2 / DNA; EC 2.7.10.1 / Receptor, ErbB-2
  •  go-up   go-down


27. Ahmad Z, Qureshi A: Primary signet ring cell carcinoma of gall bladder: report of an extremely rare histological type of primary gall bladder carcinoma. BMJ Case Rep; 2010;2010
MedlinePlus Health Information. consumer health - Gallstones.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary signet ring cell carcinoma of gall bladder: report of an extremely rare histological type of primary gall bladder carcinoma.
  • Signet ring cell carcinoma is an extremely rare type of gall bladder carcinoma composed overwhelmingly (90%) of signet ring cells.
  • It is necessary to exclude a gastric or colonic signet ring cell carcinoma secondarily involving the gall bladder.
  • The primary aim of this case report is to describe the histopathological aspects of this tumour.
  • Primary signet ring cell carcinoma of gall bladder shows dysplastic surface gall bladder epithelium with infiltration of gall bladder wall.
  • It is also necessary to exclude benign signet ring change, which sometimes occurs in the gall bladder.
  • This case showed grossly diffuse thickening of the gall bladder wall and dysplastic surface epithelium of the gall bladder on histology, with sheets of signet ring cells infiltrating full thickness of the wall.
  • It is also necessary to exclude benign signet ring cell change, which sometimes occurs in the gall bladder.
  • [MeSH-major] Carcinoma, Signet Ring Cell / pathology. Cholelithiasis / diagnosis. Cholelithiasis / surgery. Gallbladder Neoplasms / pathology
  • [MeSH-minor] Biopsy, Needle. Cholecystectomy / methods. Diagnosis, Differential. Female. Follow-Up Studies. Humans. Immunohistochemistry. Middle Aged. Mucous Membrane / pathology. Neoplasm Invasiveness / pathology. Neoplasm Staging. Pakistan. Rare Diseases. Risk Assessment

  • Genetic Alliance. consumer health - Signet ring cell carcinoma.
  • MedlinePlus Health Information. consumer health - Gallbladder Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Surg Neurol. 1988 Apr;29(4):315-8 [2832956.001]
  • [Cites] Rom J Morphol Embryol. 1991 Jul-Dec;37(3-4):171-3 [1667605.001]
  • [Cites] Adv Ther. 2008 May;25(5):520-3 [18461291.001]
  • [Cites] Pathol Res Pract. 2001;197(11):785-8 [11770024.001]
  • [Cites] Pathol Res Pract. 1998;194(3):197-200 [9587939.001]
  • [Cites] Australas J Dermatol. 2007 Aug;48(3):187-9 [17680973.001]
  • [Cites] Semin Diagn Pathol. 1996 Nov;13(4):326-38 [8946610.001]
  • [Cites] Pathol Int. 1997 Jun;47(6):368-76 [9211524.001]
  • (PMID = 22778190.001).
  • [ISSN] 1757-790X
  • [Journal-full-title] BMJ case reports
  • [ISO-abbreviation] BMJ Case Rep
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC3028283
  •  go-up   go-down


28. Niu ZB, Yang Y, Hou Y, Chen H, Liu X, Wang CL: Lymphangioma of bladder. Urology; 2010 Oct;76(4):955-7
MedlinePlus Health Information. consumer health - Bladder Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Lymphangioma of bladder.
  • Lymphangioma in the bladder is extremely rare.
  • Ultrasonography, computed tomogram, and retrograde urethrography showed a mass that was in the wall of the bladder.
  • The tumor was red and found to be bulging into the bladder on the right lateral wall of the bladder by cystoscopy.
  • A partial cystectomy was performed and histology revealed a lymphangioma of the bladder.
  • This case, to the authors' knowledge, represents the third reported case of lymphangioma of bladder.Lymphangiomas are benign, soft-tissue tumors of lymphatic origin.
  • They rarely affect the urinary system and a location in the bladder is extremely rare.
  • Only 2 cases of lymphangioma of the bladder have been reported worldwide since 1983.
  • The present report describes a patient with a lymphangioma of the bladder and the imaging characteristics of the lesion are reported, including imagings of sonography, computed tomography, retrograde urethrography, and histologic examination.
  • [MeSH-major] Lymphangioma / pathology. Urinary Bladder Neoplasms / pathology

  • Genetic Alliance. consumer health - Lymphangioma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010 Elsevier Inc. All rights reserved.
  • (PMID = 20494412.001).
  • [ISSN] 1527-9995
  • [Journal-full-title] Urology
  • [ISO-abbreviation] Urology
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  •  go-up   go-down


29. Tauber S, Stepp H, Meier R, Bone A, Hofstetter A, Stief C: Integral spectrophotometric analysis of 5-aminolaevulinic acid-induced fluorescence cytology of the urinary bladder. BJU Int; 2006 May;97(5):992-6
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Integral spectrophotometric analysis of 5-aminolaevulinic acid-induced fluorescence cytology of the urinary bladder.
  • OBJECTIVE: To evaluate whether tumour cells can be detected in bladder lavage fluid samples by an objective spectrofluorometric method, as 5-aminolaevulinic acid (ALA)-induced fluorescence endoscopy (AFE) and cytology are promising valuable tools for detecting transitional cell carcinoma of the urinary bladder (TCCB).
  • MATERIALS AND METHODS: After instilling ALA into the urinary bladder, lavage samples were collected and their sediments analysed spectroscopically under blue excitation at approximately 400 nm wavelength.
  • The PPIX signals derived from bleaching spectra were significantly different between benign and malignant findings (P = 0.001).
  • CONCLUSIONS: Spectrofluorometric analysis of lavage sample sediments can be used to detect tumour-associated red fluorescence of PPIX in TCCB.
  • Immediate significant and objective measurements are possible, which could be further automated for the rapid diagnosis of TCCB.
  • [MeSH-major] Aminolevulinic Acid. Carcinoma, Transitional Cell / pathology. Photosensitizing Agents. Urinary Bladder / pathology. Urinary Bladder Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16643481.001).
  • [ISSN] 1464-4096
  • [Journal-full-title] BJU international
  • [ISO-abbreviation] BJU Int.
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Photosensitizing Agents; 0 / Protoporphyrins; 553-12-8 / protoporphyrin IX; 88755TAZ87 / Aminolevulinic Acid
  •  go-up   go-down


30. Haylen BT: The empty bladder. Int Urogynecol J Pelvic Floor Dysfunct; 2007 Mar;18(3):237-9

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The empty bladder.
  • The empty (near-empty) bladder can have a volume ranging from 0 to 30 ml.
  • Its diagnosis is effectively and least invasively made by ultrasound (transvaginal superior).
  • It is a key marker of normal bladder function.
  • It is necessary for the accurate assessment of uterovaginal prolapse, as increasing bladder volume has been shown to reduce the extent of the prolapse.
  • Any negative effect of prolapse on voiding is reduced at high bladder volumes compared to voiding from low bladder volumes (due to the same reduction in the extent of the prolapse).
  • An empty bladder is optimal for bimanual pelvic examination and most transvaginal ultrasound examinations including that for uterine version.
  • The woman whose bladder is empty post-voiding is at a significantly lower risk of recurrent urinary tract infections.
  • The bladder that can't be emptied is a marker of bladder dysfunction, requiring a fuller investigation.
  • From a surgical point of view, the empty bladder improves access and reduces surgical risks with laparotomy, as well as both laparoscopic and vaginal surgery.
  • [MeSH-major] Urinary Bladder / physiology
  • [MeSH-minor] Female. Gynecologic Surgical Procedures. Humans. Recurrence. Urinary Tract Infections / physiopathology. Urination / physiology. Uterine Prolapse / physiopathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16791705.001).
  • [Journal-full-title] International urogynecology journal and pelvic floor dysfunction
  • [ISO-abbreviation] Int Urogynecol J Pelvic Floor Dysfunct
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


31. Naim M: Immature embryoid teratoma of the gall bladder: case of a primary primitive neoplasm. BMJ Case Rep; 2009;2009

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Immature embryoid teratoma of the gall bladder: case of a primary primitive neoplasm.
  • This study presents diagnostic histopathological features of a primary embryoid teratomatous neoplasm in the gall bladder of a 60-year-old woman, and also discusses its pathogenesis.
  • The residual endothelial lining of the gall bladder showed in situ and proliferative changes characteristic of an endodermal tumour.
  • Results show that the mature adult gall bladder is susceptible to primary neoplasms of a primitive nature ranging from immature embryoma and teratoma to neuroectodermal tumour.
  • Such primitive neoplasms in adult organs where benign neuroectodermal elements are present may evolve from a constituent cell of an adult organ acquired during embryogenesis from a morula that differentiated into trophoblastic (outer) and embryoblastic (inner) cells, and existing dormant cells at rest until reactivation during oncogenesis.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Mod Pathol. 2003 Apr;16(4):299-308 [12692194.001]
  • [Cites] Br J Surg. 1961 Jul;49:3-8 [14492775.001]
  • [Cites] Arch Pathol Lab Med. 2004 May;128(5):571-3 [15086299.001]
  • [Cites] J Postgrad Med. 2006 Oct-Dec;52(4):304-5 [17102555.001]
  • [Cites] J Pediatr Surg. 2007 Oct;42(10):E25-7 [17923185.001]
  • (PMID = 21687015.001).
  • [ISSN] 1757-790X
  • [Journal-full-title] BMJ case reports
  • [ISO-abbreviation] BMJ Case Rep
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC3027538
  •  go-up   go-down


32. Juan Escudero JU, Ramos de Campos M, Ordoño Domínguez F, Fabuel Deltoro M, Serrano de la Cruz Torrijos F, Navalón Verdejo P, López Alcina E, Zaragoza Orts J: [Inguinoscrotal bladder hernias]. Arch Esp Urol; 2007 Apr;60(3):231-6
MedlinePlus Health Information. consumer health - Bladder Diseases.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Inguinoscrotal bladder hernias].
  • In the general population, only a small percentage of them involve the bladder.
  • Bladder wall weakness and bladder outlet obstruction are involved in its pathogenesis.
  • We present our experience in the diagnosis and treatment of this rare disease.
  • METHODS: A total of eight patients have been diagnosed of inguinoscrotal bladder hernia and treated in our center over the last 18 years.
  • In most cases, retrograde and voiding cystourethrograms, prostatic and bladder ultrasound, and uroflowmetry have been performed.
  • The treatment varied depending on the characteristics of the herniated bladder tissues and bladder capacity.
  • The treatment of bladder outlet obstruction varied depending on the etiology.
  • Resection of the herniated bladder tissue was carried out in four patients due to the quality of the tissue; bladder-pexy to the abdominis rectus muscles was performed in one patient; hernia repair with bladder reintroduction was the treatment in the other four cases.
  • Bladder outlet obstruction was treated in six cases.
  • Seven patients showed clinical improvement, showing normal bladder morphology on post operative cystogram.
  • CONCLUSIONS: Bladder hernia is a rare pathology often presenting in mid age males.
  • It should be suspected in every male with lower urinary tract obstructive symptoms and associated inguinal hernia.
  • The treatment of choice is that of the hernia and bladder outlet obstruction.
  • [MeSH-major] Genital Diseases, Male / diagnosis. Genital Diseases, Male / surgery. Hernia, Inguinal / diagnosis. Hernia, Inguinal / surgery. Scrotum. Urinary Bladder Diseases / diagnosis. Urinary Bladder Diseases / surgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17601297.001).
  • [ISSN] 0004-0614
  • [Journal-full-title] Archivos españoles de urología
  • [ISO-abbreviation] Arch. Esp. Urol.
  • [Language] spa
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Spain
  • [Number-of-references] 16
  •  go-up   go-down


33. Heinzelbecker J, Becker F, Pflugmann T, Friemann J, Walz PH: Solitary fibrous tumour of the urinary bladder in a young woman presenting with haemodynamic-relevant gross haematuria. Eur Urol; 2008 Nov;54(5):1188-91
MedlinePlus Health Information. consumer health - Bladder Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Solitary fibrous tumour of the urinary bladder in a young woman presenting with haemodynamic-relevant gross haematuria.
  • A 24-yr-old woman presented with gross haematuria and a huge tumour of the right bladder wall.
  • At transurethral resection, a solid tumour was seen covered with normal mucosa.
  • The pathological evaluation revealed a solitary fibrous tumour (SFT) of the urinary bladder.
  • For final treatment, a partial cystectomy was performed; tumour-free margins were ensured by frozen-section analysis.
  • Due to the difficulty in discriminating between malignant and benign growth pattern of this tumour entity, a regular follow-up after conservative treatment is mandatory.
  • [MeSH-major] Hematuria / etiology. Hemodynamics / physiology. Solitary Fibrous Tumors / complications. Urinary Bladder Neoplasms / complications
  • [MeSH-minor] Cystectomy / methods. Cystoscopy. Diagnosis, Differential. Female. Follow-Up Studies. Humans. Magnetic Resonance Imaging. Tomography, X-Ray Computed. Young Adult

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18692954.001).
  • [ISSN] 0302-2838
  • [Journal-full-title] European urology
  • [ISO-abbreviation] Eur. Urol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Switzerland
  •  go-up   go-down


34. Moreira JM, Ohlsson G, Gromov P, Simon R, Sauter G, Celis JE, Gromova I: Bladder cancer-associated protein, a potential prognostic biomarker in human bladder cancer. Mol Cell Proteomics; 2010 Jan;9(1):161-77
MedlinePlus Health Information. consumer health - Bladder Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Bladder cancer-associated protein, a potential prognostic biomarker in human bladder cancer.
  • It is becoming increasingly clear that no single marker will have the sensitivity and specificity necessary to be used on its own for diagnosis/prognosis of tumors.
  • As a result of these studies, we have identified and reported several candidate biomarker proteins that are deregulated in bladder cancer.
  • Following the conceptual biomarker development phases proposed by the Early Detection Research Network, we have taken some of the most promising candidate proteins into postdiscovery validation studies, and here we report on the characterization of one such biomarker, the bladder cancer-associated protein (BLCAP), formerly termed Bc10.
  • To characterize BLCAP protein expression and cellular localization patterns in benign bladder urothelium and urothelial carcinomas (UCs), we used two independent sets of samples from different patient cohorts: a reference set consisting of 120 bladder specimens (formalin-fixed as well as frozen biopsies) and a validation set consisting of 2,108 retrospectively collected UCs with long term clinical follow-up.
  • We could categorize the UCs examined into four groups based on levels of expression and subcellular localization of BLCAP protein and showed that loss of BLCAP expression is associated with tumor progression.
  • [MeSH-major] Biomarkers, Tumor / analysis. Neoplasm Proteins / analysis. Proteomics / methods. Urinary Bladder Neoplasms / metabolism

  • Genetic Alliance. consumer health - Bladder cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Cell Sci. 2001 Aug;114(Pt 16):2891-3 [11686292.001]
  • [Cites] Am J Clin Pathol. 2001 Oct;116(4):495-503 [11601134.001]
  • [Cites] Int J Cancer. 2002 Apr 1;98(4):539-46 [11920613.001]
  • [Cites] Neuron. 2002 Apr 25;34(3):349-56 [11988167.001]
  • [Cites] Mol Cell Proteomics. 2002 Apr;1(4):269-79 [12096109.001]
  • [Cites] Anticancer Res. 2002 Nov-Dec;22(6B):3759-64 [12552989.001]
  • [Cites] Cancer Cell. 2003 Jan;3(1):9-15 [12559171.001]
  • [Cites] Science. 2003 Aug 8;301(5634):832-6 [12907802.001]
  • [Cites] Nature. 2004 Feb 26;427(6977):801 [14985749.001]
  • [Cites] Mol Cell Proteomics. 2004 Apr;3(4):410-9 [14736829.001]
  • [Cites] Pharmacogenomics. 2004 Jun;5(4):381-94 [15165174.001]
  • [Cites] Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi. 2003 Sep;19(5):465-6 [15169658.001]
  • [Cites] J Mol Biol. 2004 Jul 16;340(4):783-95 [15223320.001]
  • [Cites] Prostate. 2004 Nov 1;61(3):215-27 [15368473.001]
  • [Cites] Acta Chir Scand. 1965 Oct;130(4):371-8 [5842510.001]
  • [Cites] Virchows Arch A Pathol Anat Histol. 1981;391(2):217-25 [6784337.001]
  • [Cites] Cell. 1991 Oct 4;67(1):11-9 [1717158.001]
  • [Cites] Urol Clin North Am. 1992 Aug;19(3):429-33 [1636228.001]
  • [Cites] Science. 1995 Dec 8;270(5242):1677-80 [7502080.001]
  • [Cites] Cancer Res. 1996 Oct 15;56(20):4782-90 [8840999.001]
  • [Cites] Nature. 1997 May 15;387(6630):303-8 [9153397.001]
  • [Cites] Cancer Res. 1997 Sep 15;57(18):4111-7 [9307301.001]
  • [Cites] Int J Oncol. 1998 Aug;13(2):379-83 [9664136.001]
  • [Cites] Electrophoresis. 1999 Feb;20(2):241-8 [10197429.001]
  • [Cites] Electrophoresis. 1999 Feb;20(2):349-54 [10197442.001]
  • [Cites] Hybrid Hybridomics. 2004 Dec;23(6):335-42 [15684659.001]
  • [Cites] Nucleic Acids Res. 2005;33(4):1162-8 [15731336.001]
  • [Cites] Mol Cell Proteomics. 2005 Apr;4(4):570-81 [15734831.001]
  • [Cites] Bioinformatics. 2005 May 1;21(9):1853-8 [15691854.001]
  • [Cites] Bioinformatics. 2005 Jun 1;21(11):2590-5 [15797904.001]
  • [Cites] Nucleic Acids Res. 2005 Jul 1;33(Web Server issue):W226-9 [15980458.001]
  • [Cites] Tumour Biol. 2006;27(4):221-6 [16675915.001]
  • [Cites] Ai Zheng. 2006 Jul;25(7):811-7 [16831269.001]
  • [Cites] Cell. 2006 Dec 1;127(5):1071 [17129789.001]
  • [Cites] Nat Struct Mol Biol. 2007 Mar;14(3):185-93 [17310252.001]
  • [Cites] Mol Cell Biochem. 2007 Mar;297(1-2):81-92 [17031575.001]
  • [Cites] Genome Res. 2007 Nov;17(11):1586-95 [17908822.001]
  • [Cites] J Clin Epidemiol. 2007 Dec;60(12):1205-19 [17998073.001]
  • [Cites] J Biol Chem. 2008 Mar 14;283(11):7251-60 [18178553.001]
  • [Cites] RNA. 2008 Jun;14(6):1110-8 [18430892.001]
  • [Cites] Ann N Y Acad Sci. 2008;1131:1-12 [18519955.001]
  • [Cites] Cancer Cell. 2008 Jun;13(6):554-6 [18538738.001]
  • [Cites] Urology. 2008 Sep;72(3):706-10 [18342921.001]
  • [Cites] Scand J Urol Nephrol Suppl. 2008 Sep;(218):12-20 [19054893.001]
  • [Cites] Tumour Biol. 2008;29(5):311-22 [18984977.001]
  • [Cites] RNA Biol. 2008 Oct-Dec;5(4):193-7 [18971634.001]
  • [Cites] Mol Oncol. 2007 Dec;1(3):321-49 [19383306.001]
  • [Cites] Mol Oncol. 2008 Apr;1(4):384-94 [19383312.001]
  • [Cites] Mol Oncol. 2008 Apr;1(4):406-12 [19383314.001]
  • [Cites] Mol Oncol. 2008 Aug;2(2):153-60 [19383334.001]
  • [Cites] Mol Oncol. 2008 Oct;2(3):213-22 [19383342.001]
  • [Cites] Urol Oncol. 2011 Jan-Feb;29(1):21-6 [19186082.001]
  • [Cites] J Mol Biol. 1999 Dec 17;294(5):1351-62 [10600390.001]
  • [Cites] Clin Cancer Res. 1999 Dec;5(12):4079-84 [10632343.001]
  • [Cites] EXS. 2000;88:55-67 [10803371.001]
  • [Cites] Am J Pathol. 2000 Sep;157(3):787-94 [10980118.001]
  • [Cites] Int J Cancer. 2000 Dec 1;88(5):726-32 [11072240.001]
  • [Cites] J Mol Biol. 2001 Jan 19;305(3):567-80 [11152613.001]
  • [Cites] J Pathol. 2001 Jul;194(3):349-57 [11439368.001]
  • [Cites] J Natl Cancer Inst. 2001 Jul 18;93(14):1054-61 [11459866.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Dec 4;98(25):14687-92 [11717408.001]
  • (PMID = 19783793.001).
  • [ISSN] 1535-9484
  • [Journal-full-title] Molecular & cellular proteomics : MCP
  • [ISO-abbreviation] Mol. Cell Proteomics
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / BLCAP protein, human; 0 / Biomarkers, Tumor; 0 / Membrane Proteins; 0 / Neoplasm Proteins
  • [Other-IDs] NLM/ PMC2808262
  •  go-up   go-down


35. Simo AK, Lemelle JL, Ranke A, de Miscault G, Schmitt M: [Nephrogenic adenoma of the bladder in children younger than 10 years: report of 5 cases]. Prog Urol; 2006 Sep;16(4):485-8
MedlinePlus Health Information. consumer health - Bladder Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Nephrogenic adenoma of the bladder in children younger than 10 years: report of 5 cases].
  • [Transliterated title] Adénome néphrogénique de la vessie chez l'enfant de moins de 10 ans: a propos de 5 cas.
  • INTRODUCTION: Nephrogenic adenoma (NA) of the bladder is a rare transitional cell tumour of the bladder in children under the age of 10 years.
  • RESULTS: All patients presented a risk factor for bladder irritation.
  • Initial symptoms were nonspecific and radiology contributed to the diagnosis in two cases.
  • One recurrence was observed 8 years after the initial diagnosis, but no cases of malignant transformation were observed during follow-up.
  • CONCLUSION: NA of the bladder is a benign tumour which does not predispose to malignancy.
  • Urine cytology could contribute to the diagnosis of recurrence.
  • [MeSH-major] Adenoma / surgery. Urinary Bladder Neoplasms / surgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17069045.001).
  • [ISSN] 1166-7087
  • [Journal-full-title] Progrès en urologie : journal de l'Association française d'urologie et de la Société française d'urologie
  • [ISO-abbreviation] Prog. Urol.
  • [Language] fre
  • [Publication-type] Comparative Study; English Abstract; Journal Article; Review
  • [Publication-country] France
  • [Number-of-references] 30
  •  go-up   go-down


36. Schultz L, Albadine R, Hicks J, Jadallah S, DeMarzo AM, Chen YB, Nielsen ME, Gonzalgo ML, Sidransky D, Schoenberg M, Netto GJ: Expression status and prognostic significance of mammalian target of rapamycin pathway members in urothelial carcinoma of urinary bladder after cystectomy. Cancer; 2010 Dec 1;116(23):5517-26
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression status and prognostic significance of mammalian target of rapamycin pathway members in urothelial carcinoma of urinary bladder after cystectomy.
  • BACKGROUND: Bladder urothelial carcinoma has high rates of mortality and morbidity.
  • Pten showed loss of expression in 35% of bladder urothelial carcinoma.
  • All markers showed lower expression in invasive bladder urothelial carcinoma compared with benign urothelium with the exception of 4E-BP1.
  • CONCLUSIONS: We found an overall down-regulation of mTOR pathway in bladder urothelial carcinoma. phosS6 independently predicted DSS, and c-myc independently predicted progression.

  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010 American Cancer Society.
  • [Cites] J Clin Oncol. 2001 Feb 1;19(3):666-75 [11157016.001]
  • [Cites] Med Oncol. 2010 Jun;27(2):255-61 [19301157.001]
  • [Cites] Cell. 2002 Jul 26;110(2):163-75 [12150925.001]
  • [Cites] Cell Cycle. 2002 Nov-Dec;1(6):394-400 [12548012.001]
  • [Cites] Endocr J. 2003 Feb;50(1):77-83 [12733712.001]
  • [Cites] BJU Int. 2004 Jan;93(1):143-50 [14678387.001]
  • [Cites] Br J Cancer. 2004 Apr 19;90(8):1543-50 [15083183.001]
  • [Cites] Eur Urol. 2004 Aug;46(2):200-8 [15245814.001]
  • [Cites] Genes Dev. 2004 Aug 15;18(16):1926-45 [15314020.001]
  • [Cites] Oncogene. 2004 Sep 23;23(44):7378-90 [15286700.001]
  • [Cites] Cancer Res. 1996 Sep 1;56(17):3895-7 [8752154.001]
  • [Cites] FEBS Lett. 1999 Mar 5;446(1):55-9 [10100614.001]
  • [Cites] Cancer Res. 1999 Jul 1;59(13):3245-50 [10397272.001]
  • [Cites] Clin Cancer Res. 2004 Dec 15;10(24):8421-5 [15623621.001]
  • [Cites] Methods Mol Med. 2005;103:89-101 [15542899.001]
  • [Cites] Urol Int. 2005;75(2):102-6 [16123561.001]
  • [Cites] Oncol Rep. 2005 Oct;14(4):909-13 [16142350.001]
  • [Cites] Nat Rev Cancer. 2005 Sep;5(9):713-25 [16110317.001]
  • [Cites] Mod Pathol. 2006 Feb;19(2):238-45 [16341149.001]
  • [Cites] Cancer Res. 2006 Feb 15;66(4):1929-39 [16488991.001]
  • [Cites] Mol Cell Biol. 2006 May;26(10):3955-65 [16648488.001]
  • [Cites] Nat Rev Cancer. 2006 Sep;6(9):729-34 [16915295.001]
  • [Cites] Urol Int. 2006;77(3):255-63 [17033215.001]
  • [Cites] Cancer. 2006 Oct 15;107(8):1801-11 [16983702.001]
  • [Cites] Zhonghua Yi Xue Za Zhi. 2006 Jul 25;86(28):1970-4 [17064593.001]
  • [Cites] J Urol. 2007 Feb;177(2):481-7; discussion 487 [17222615.001]
  • [Cites] Virchows Arch. 2007 Mar;450(3):321-8 [17265080.001]
  • [Cites] Cancer. 2007 Jun 1;109(11):2257-67 [17440983.001]
  • [Cites] BJU Int. 2007 Aug;100(2):259-63 [17555476.001]
  • [Cites] Curr Opin Urol. 2008 Jan;18(1):1-8 [18090481.001]
  • [Cites] Biochim Biophys Acta. 2008 Jan;1784(1):150-8 [17964232.001]
  • [Cites] J Clin Pathol. 2008 May;61(5):658-64 [17908805.001]
  • [Cites] Mol Carcinog. 2008 Sep;47(9):678-85 [18288642.001]
  • [Cites] Ann Clin Lab Sci. 2008 Summer;38(3):195-209 [18715846.001]
  • [Cites] Scand J Urol Nephrol Suppl. 2008 Sep;(218):154-65 [18815930.001]
  • [Cites] Nat Rev Cancer. 2008 Nov;8(11):851-64 [18846101.001]
  • [Cites] Tumour Biol. 2008;29(5):311-22 [18984977.001]
  • [Cites] Biochem Soc Trans. 2009 Feb;37(Pt 1):217-22 [19143635.001]
  • [Cites] Liver Int. 2009 Mar;29(3):399-405 [18492014.001]
  • [Cites] Genes Dev. 2009 Mar 15;23(6):675-80 [19261747.001]
  • [Cites] Oncogene. 2009 Apr 2;28(13):1594-604 [19234517.001]
  • [Cites] Cell Cycle. 2009 May 1;8(9):1344-51 [19342893.001]
  • [Cites] Nat Genet. 2009 May;41(5):524-6 [19396167.001]
  • [Cites] Nat Genet. 2009 May;41(5):619-24 [19396168.001]
  • [Cites] Hepatogastroenterology. 2009 Jan-Feb;56(89):6-10 [19453019.001]
  • [Cites] Mod Pathol. 2009 Jun;22 Suppl 2:S70-95 [19494855.001]
  • [Cites] Clin Cancer Res. 2009 Oct 1;15(19):6008-17 [19789314.001]
  • [Cites] Cancer Res. 2009 Nov 1;69(21):8256-64 [19843858.001]
  • [Cites] J Urol. 2010 Jan;183(1):68-75 [19913255.001]
  • [ErratumIn] Cancer. 2011 Nov 1;117(21):5021. Neilsen, Matthew E [corrected to Nielsen, Matthew E]
  • (PMID = 20939013.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA077664-10; United States / NCI NIH HHS / CA / P01 CA077664; United States / NCI NIH HHS / CA / P50 CA058236; United States / NCI NIH HHS / CA / P01 CA077664-10
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; EC 2.7.1.1 / MTOR protein, human; EC 2.7.1.1 / TOR Serine-Threonine Kinases
  • [Other-IDs] NLM/ NIHMS214322; NLM/ PMC3568488
  •  go-up   go-down


37. Charfi S, Moussa A, Njim L, Toffahi M, Hadhri R, Mahmoudi H, Zakhama A: [Micropapillary bladder carcinoma]. Prog Urol; 2006 Nov;16(5):607-9
MedlinePlus Health Information. consumer health - Bladder Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Micropapillary bladder carcinoma].
  • [Transliterated title] Carcinome micropapillaire de la vessie.
  • Micropapillary bladder carcinoma is a recently described, rare variant of urothelial carcinoma reputed for its poor prognosis.
  • The authors report the case of a 59-year-old man with invasive bladder tumour presenting with haematuria.
  • The authors discuss the clinicopathological and pathogenic features, treatment and clinical course of this tumour.
  • [MeSH-major] Carcinoma, Papillary / pathology. Urinary Bladder Neoplasms / pathology
  • [MeSH-minor] Hematuria / etiology. Humans. Male. Middle Aged. Neoplasm Invasiveness

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17175962.001).
  • [ISSN] 1166-7087
  • [Journal-full-title] Progrès en urologie : journal de l'Association française d'urologie et de la Société française d'urologie
  • [ISO-abbreviation] Prog. Urol.
  • [Language] fre
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] France
  •  go-up   go-down


38. Roperto S, Borzacchiello G, Casellato R, Galati P, Russo V, Sonnino S, Roperto F: Sialic acid and GM3 ganglioside expression in papillomavirus-associated urinary bladder tumours of cattle with chronic enzootic haematuria. J Comp Pathol; 2007 Aug-Oct;137(2-3):87-93
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Sialic acid and GM3 ganglioside expression in papillomavirus-associated urinary bladder tumours of cattle with chronic enzootic haematuria.
  • This study was based on 30 papillomavirus-associated urinary bladder tumours from cattle with chronic haematuria, the animals having been kept since birth on pasture rich in bracken fern.
  • The ganglioside content was assessed and compared with that of normal bovine urinary bladders, which was shown to be 28.6+/-3.3 (mean+/-SD) microg of lipid-bound sialic acid per gram of fresh tissue.
  • In neoplastic bladder samples this value was higher but variable (120.9+/-80.6 in benign tumours, and 94.7+/-45.7 in malignant tumours).
  • The main ganglioside, GM3, represented ca 75% of the total ganglioside mixture in normal tissues and 50-80% in tumour samples.
  • [MeSH-major] Bovine papillomavirus 1 / pathogenicity. Cattle Diseases / metabolism. G(M3) Ganglioside / metabolism. Hematuria / veterinary. N-Acetylneuraminic Acid / metabolism. Papillomavirus Infections / veterinary. Urinary Bladder Neoplasms / veterinary
  • [MeSH-minor] Animals. Cattle. Down-Regulation. Glycosphingolipids / metabolism. Urinary Bladder / metabolism. Urinary Bladder / pathology. Urinary Bladder / virology

  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17624364.001).
  • [ISSN] 0021-9975
  • [Journal-full-title] Journal of comparative pathology
  • [ISO-abbreviation] J. Comp. Pathol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / G(M3) Ganglioside; 0 / Glycosphingolipids; GZP2782OP0 / N-Acetylneuraminic Acid
  •  go-up   go-down


39. Blah M, Nouira Y, Kallel Y, Hafsia GH, Horchani A: [Bladder herniation]. Ann Chir; 2005 Dec;130(10):633-5
MedlinePlus Health Information. consumer health - Bladder Diseases.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Bladder herniation].
  • Inguinal hernia of the bladder is uncommon.
  • The diagnosis is frequently done during surgery.
  • It can be evoked before surgery when the patient presents with irritative and obstructive lower urinary tract symptoms.
  • Retrograde urethrocystography or computerized tomography confirm the diagnosis.
  • We report a case of bilateral inguinal hernia involving the bladder at the right side in a 87 years old man who had a surgical history of transvesical adenomectomy of the prostate.
  • The diagnosis was done on the retrograde urethrocystography.
  • We performed bilateral herniorrhaphy with herniated bladder reduction.
  • [MeSH-major] Hernia, Inguinal / surgery. Urinary Bladder Diseases / surgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16043116.001).
  • [ISSN] 0003-3944
  • [Journal-full-title] Annales de chirurgie
  • [ISO-abbreviation] Ann Chir
  • [Language] fre
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] France
  •  go-up   go-down


40. Rochester MA, Patel N, Turney BW, Davies DR, Roberts IS, Crew J, Protheroe A, Macaulay VM: The type 1 insulin-like growth factor receptor is over-expressed in bladder cancer. BJU Int; 2007 Dec;100(6):1396-401
MedlinePlus Health Information. consumer health - Bladder Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The type 1 insulin-like growth factor receptor is over-expressed in bladder cancer.
  • OBJECTIVE: To analyse bladder cancer biopsies and investigate the pattern of expression of the type 1 insulin-like growth factor receptor (IGF1R), a receptor tyrosine kinase that mediates tumour cell proliferation, motility and protection from apoptosis.
  • MATERIALS AND METHODS: Formalin-fixed specimens of bladder cancer (40 whole-mount, 80 cores on a tumour microarray) and normal bladder (15 samples) were stained immunohistochemically for the IGF1R.
  • The IGF1R expression was also measured by quantitative reverse transcription-polymerase chain reaction (Q-RT-PCR) on RNA extracted from fresh frozen bladder cancers (61) and benign bladder (12).
  • RESULTS: Of the 15 samples of normal bladder, 14 showed negligible (1+) or light (2+) IGF1R immunostaining.
  • Q-RT-PCR showed significantly higher levels of steady-state IGF1R mRNA in tumours (all cases, Ta-T4) than in normal bladder (P < 0.05), indicating up-regulation at the transcriptional level.
  • This difference was particularly evident when comparing normal urothelium with superficial (Ta-T1) or invasive (T2-4) tumours; only the latter showed significant IGF1R over-expression at the RNA level (P < 0.05 vs normal bladder).
  • CONCLUSION: The IGF1R is up-regulated in bladder cancer compared with non-malignant bladder, and might contribute to a propensity for invasion.
  • [MeSH-major] Neoplasm Proteins / metabolism. Receptor, IGF Type 1 / metabolism. Urinary Bladder Neoplasms / metabolism
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Biopsy, Needle. Cell Proliferation. Female. Humans. Immunohistochemistry. Male. Middle Aged. Neoplasm Invasiveness. Prospective Studies. Reverse Transcriptase Polymerase Chain Reaction. Up-Regulation

  • Genetic Alliance. consumer health - Bladder cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17645417.001).
  • [ISSN] 1464-410X
  • [Journal-full-title] BJU international
  • [ISO-abbreviation] BJU Int.
  • [Language] eng
  • [Grant] United Kingdom / Medical Research Council / / MRC/ G0601061
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Neoplasm Proteins; EC 2.7.10.1 / Receptor, IGF Type 1
  •  go-up   go-down


41. Grima F, Golfier F, Raudrant D: [Clinicopathological correlation in bladder endometriosis]. Prog Urol; 2005 Jun;15(3):498-500
MedlinePlus Health Information. consumer health - Endometriosis.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Clinicopathological correlation in bladder endometriosis].
  • Bladder endometriosis is a rare site of a disease with very polymorphic clinical signs.
  • The authors report the case of a 30-year-old woman operated for bladder endometriosis who presented with recent menstrual macroscopic haematuria with primary infertility and deep dyspareunia.
  • Histological examination demonstrated bladder endometriosis sparing the urothelium.
  • Comparison with our histological series of bladder endometriosis demonstrated polymorphic lesions ranging from integrity to complete loss of the bladder mucosa, with no correlation with clinical features.
  • [MeSH-major] Endometriosis / pathology. Urinary Bladder Diseases / pathology

  • Genetic Alliance. consumer health - Endometriosis.
  • MedlinePlus Health Information. consumer health - Bladder Diseases.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16097157.001).
  • [ISSN] 1166-7087
  • [Journal-full-title] Progrès en urologie : journal de l'Association française d'urologie et de la Société française d'urologie
  • [ISO-abbreviation] Prog. Urol.
  • [Language] fre
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] France
  •  go-up   go-down


42. Kavia R, Mumtaz F: Overactive bladder. J R Soc Promot Health; 2005 Jul;125(4):176-9
MedlinePlus Health Information. consumer health - Urinary Incontinence.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Overactive bladder.
  • Overactive bladder (OAB) is defined as urgency, with or without urge incontinence, usually with frequency and nocturia, in the absence of local pathological or hormonal factors.
  • ApproximateLy 70% of men with bladder outflow obstruction will have some symptoms of OAB.
  • The exact pathophysiology of OAB in bladder outflow obstruction is yet to be elucidated; evidence to date points to changes in both the efferent and afferent innervation and the detrusor.
  • More specific treatment options for OAB in bladder outflow obstruction include relief of the obstruction with surgical (e.g. transurethraL resection of prostate) or pharmaceutical (e.g. a blockers) methods.
  • [MeSH-major] Urinary Bladder Diseases / therapy. Urinary Incontinence / therapy

  • MedlinePlus Health Information. consumer health - Bladder Diseases.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16094929.001).
  • [ISSN] 1466-4240
  • [Journal-full-title] The journal of the Royal Society for the Promotion of Health
  • [ISO-abbreviation] J R Soc Promot Health
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Anti-Dyskinesia Agents; 0 / Muscarinic Antagonists; 0 / Muscle Relaxants, Central
  • [Number-of-references] 21
  •  go-up   go-down


43. Ecke TH, Schlechte HH, Schulze G, Lenk SV, Loening SA: Four tumour markers for urinary bladder cancer--tissue polypeptide antigen (TPA), HER-2/neu (ERB B2), urokinase-type plasminogen activator receptor (uPAR) and TP53 mutation. Anticancer Res; 2005 Jan-Feb;25(1B):635-41
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Four tumour markers for urinary bladder cancer--tissue polypeptide antigen (TPA), HER-2/neu (ERB B2), urokinase-type plasminogen activator receptor (uPAR) and TP53 mutation.
  • Mutations of the tumour suppressor gene P53 (TP53) are frequently correlated with tumour development and progression.
  • We compared TPA, HER-2/neu and uPAR, and TP53 mutation in tumour-free and bladder cancer patients.
  • MATERIALS AND METHODS: Clinical samples were used from 60 patients with tumours of the urinary bladder and from 9 patients with benign urological diseases.
  • RESULTS: Pathological concentrations of TPA, HER-2/neu and uPAR are detectable in the serum and in urine of bladder cancer patients.
  • Pathological levels of TPA in serum (p=0.001) and HER-2/neu (p =0.001) were significantly higher in patients with bladder cancer in comparison to the control group.
  • For superficial bladder cancer, the mutation frequency in TP53 was 50%, while for invasive bladder cancer the mutation frequency in TP53 was 100%.
  • Elevated TPA, HER-2/neu and uPAR levels were associated with all grades and stages of bladder cancer.
  • CONCLUSION: TPA, HER-2/neu or uPAR can differ between bladder cancer patients and the control group, but not between superficial and invasive bladder cancer.
  • TP53 mutation frequently occurs in higher stages of bladder tumours.
  • [MeSH-major] Biomarkers, Tumor / metabolism. Genes, p53 / genetics. Mutation. Receptor, ErbB-2 / biosynthesis. Receptors, Cell Surface / biosynthesis. Tissue Polypeptide Antigen / biosynthesis. Tumor Suppressor Protein p53 / biosynthesis. Urinary Bladder Neoplasms / metabolism

  • Genetic Alliance. consumer health - Bladder cancer.
  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15816639.001).
  • [ISSN] 0250-7005
  • [Journal-full-title] Anticancer research
  • [ISO-abbreviation] Anticancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Glycoproteins; 0 / PLAUR protein, human; 0 / Receptors, Cell Surface; 0 / Receptors, Urokinase Plasminogen Activator; 0 / Tissue Polypeptide Antigen; 0 / Tumor Suppressor Protein p53; EC 2.7.10.1 / Receptor, ErbB-2
  •  go-up   go-down


44. Lebret T: [Infiltrating bladder tumours]. Rev Prat; 2007 Mar 31;57(6):630-40
MedlinePlus Health Information. consumer health - Bladder Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Infiltrating bladder tumours].
  • [Transliterated title] Tumeurs infiltrantes de la vessie.
  • Invasive bladder tumours are defined as carcinomas infiltrating the muscular fibbers of the bladder wall.
  • The assessment of tumour extension includes a clinical examination and an abdominopelvic computed tomography.
  • In patients with in situ bladder cancers, this treatment results in a five-year specific survival of 90 percent.
  • After bladder resection, several types of urinary diversion may be considered.
  • The efficiency of the neobladder should be monitored regularly to ensure a satisfactory urinary voiding as well as continence acquisition, which can be achieved through auto-rehabilitation.
  • [MeSH-major] Urinary Bladder Neoplasms / pathology. Urinary Bladder Neoplasms / surgery
  • [MeSH-minor] Cystectomy. Diagnostic Imaging. Humans. Neoplasm Invasiveness. Urinary Diversion

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17593787.001).
  • [ISSN] 0035-2640
  • [Journal-full-title] La Revue du praticien
  • [ISO-abbreviation] Rev Prat
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] France
  • [Number-of-references] 10
  •  go-up   go-down


45. Hillard T: The postmenopausal bladder. Menopause Int; 2010 Jun;16(2):74-80
MedlinePlus Health Information. consumer health - Urinary Incontinence.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The postmenopausal bladder.
  • The bladder and its surrounding structures are rich in estrogen receptors and there are demonstrable physiological and anatomical changes that occur around and immediately after the menopause.
  • The prevalence of many bladder symptoms, such as frequency, urgency and incontinence, does seem to increase around the menopause, but there is continuing debate over whether these effects are due to ageing, menopause or a combination of the two.
  • The impact of the menopause varies with individual symptoms; stress urinary incontinence being associated more with estrogen deficiency than urge incontinence which seems to be more age-related.
  • Based on these effects, it could be anticipated that estrogen replacement would have a positive effect on bladder symptoms.
  • It seems that topical estrogens do have some positive effects, particularly on symptoms of urgency, frequency and urge incontinence, the prevention of urogenital atrophy and in the prevention of recurrent urinary tract infections.
  • The possible explanations for this apparent contradiction are explored, but based on current evidence, it would appear preferable to use vaginal estrogens rather than systemic as part of the management of menopause-related bladder problems.
  • [MeSH-major] Estrogen Replacement Therapy. Postmenopause / physiology. Urinary Bladder / physiopathology. Urinary Incontinence / etiology. Urinary Incontinence / physiopathology
  • [MeSH-minor] Administration, Intravaginal. Age Factors. Female. Humans. Receptors, Estrogen / physiology. Receptors, Progesterone / physiology. Urinary Tract Infections / prevention & control

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20729499.001).
  • [ISSN] 1754-0461
  • [Journal-full-title] Menopause international
  • [ISO-abbreviation] Menopause Int
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Receptors, Estrogen; 0 / Receptors, Progesterone
  •  go-up   go-down


46. Hautmann RE: [Ileal bladder substitute]. Urologe A; 2008 Jan;47(1):33-4, 36-40

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Ileal bladder substitute].
  • The history of urinary diversion in general began in 1852 and started right away with continent diversion, i.e., ureterosigmoidostomy.
  • They replaced the bladder by an isoperistaltic ileal segment which was interposed between ureters and urethra in a female dog.
  • In 1951 Couvelaire reactivated this idea of an ileal bladder substitute.
  • Retrospectively many disappointing results of urinary diversion were often not caused by insufficient competence of the outlet mechanism, but because the intestinal reservoir maintained its peristaltic properties causing high pressure peaks.
  • Transsection of the circular intestinal musculature when performing bladder augmentation had already been published by Rutkowski in 1899, Tasker in 1953, and Giertz in 1957.
  • Reflux prevention in neobladders is even less important than in a normal bladder.
  • In these patients life is similar to that in individuals with a native lower urinary tract.
  • Until a better solution is devised orthotopic bladder reconstruction remains the best option for patients requiring cystectomy.
  • [MeSH-major] Urinary Diversion / history. Urinary Reservoirs, Continent / history

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Br J Urol. 1996 Dec;78(6):840-6 [9014706.001]
  • [Cites] J Urol. 2006 Jan;175(1):185-9; discussion 189 [16406905.001]
  • [Cites] J Urol. 1987 Nov;138(5):1150-4 [3312639.001]
  • [Cites] Ann R Coll Surg Engl. 1970 Jun;46(6):320-37 [5420581.001]
  • [Cites] Br J Urol. 1953 Dec;25(4):349-57 [13115674.001]
  • [Cites] Urol Res. 1985;13(5):243-7 [4060368.001]
  • [Cites] J Urol. 1953 Oct;70(4):600-4 [13097637.001]
  • [Cites] Ann Surg. 1943 Jan;117(1):106-9 [17858159.001]
  • [Cites] Arch Surg. 1969 Aug;99(2):223-31 [5794896.001]
  • [Cites] Urol Clin North Am. 1986 May;13(2):321-31 [3515728.001]
  • [Cites] Urologe A. 1987 Mar;26(2):67-73 [3296394.001]
  • [Cites] Eur Urol. 1976;2(1):8-12 [971687.001]
  • [Cites] J Urol. 2005 Jan;173(1):144-7 [15592057.001]
  • [Cites] J Urol. 1957 Dec;78(6):683-720 [13482070.001]
  • [Cites] Acta Chir Scand. 1957 Oct 4;113(3):218-28 [13478409.001]
  • [Cites] Eur Urol. 1988;14 Suppl 1:36-40 [3181240.001]
  • [Cites] J Urol. 2005 Feb;173(2):482-4 [15643221.001]
  • [Cites] J Urol. 2003 Mar;169(3):834-42 [12576795.001]
  • [Cites] J Urol Medicale Chir. 1951;57(6):408-17 [14889638.001]
  • [Cites] J Urol. 1996 Dec;156(6):1913-7 [8911354.001]
  • [Cites] World J Urol. 2006 Aug;24(3):305-14 [16830152.001]
  • (PMID = 18210063.001).
  • [ISSN] 1433-0563
  • [Journal-full-title] Der Urologe. Ausg. A
  • [ISO-abbreviation] Urologe A
  • [Language] ger
  • [Publication-type] English Abstract; Historical Article; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


47. Zhang X, Gupta R, Nicastri AD: Bladder adenocarcinoma following gastrocystoplasty. J Pediatr Urol; 2010 Oct;6(5):525-7
MedlinePlus Health Information. consumer health - Bladder Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Bladder adenocarcinoma following gastrocystoplasty.
  • Bladder augmentation with segments of small bowel (ileocystoplasty), large intestine (colocystoplasty) or stomach (gastrocystoplasty) has been used to treat patients with small or noncompliant bladders by increasing the capacity or compliance.
  • Carcinomas following gastrocystoplasty have been observed in the segments of stomach; however, to our knowledge, carcinoma arising in the residual native bladder has not been reported.
  • We report the first case of adenocarcinoma arising in the residual native bladder in association with intestinal metaplasia and dysplasia of bladder mucosa 17 years following gastrocystoplasty.
  • Intestinal metaplasia secondary to recurrent urinary infection, chronic inflammation, and some form of irritation may potentiate the development of native bladder adenocarcinoma.
  • Patients with gastrocystoplasty are at an increased risk for carcinoma in stomach segments and require close long-term follow up; however, the risk of carcinoma in native bladder is still unclear.
  • [MeSH-major] Adenocarcinoma / etiology. Urinary Bladder / surgery. Urinary Bladder Neoplasms / etiology. Urologic Surgical Procedures / adverse effects

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010 Journal of Pediatric Urology Company. Published by Elsevier Ltd. All rights reserved.
  • (PMID = 20392671.001).
  • [ISSN] 1873-4898
  • [Journal-full-title] Journal of pediatric urology
  • [ISO-abbreviation] J Pediatr Urol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  •  go-up   go-down


48. Patrick DJ, Fitzgerald SD, Sesterhenn IA, Davis CJ, Kiupel M: Classification of canine urinary bladder urothelial tumours based on the World Health Organization/International Society of Urological Pathology consensus classification. J Comp Pathol; 2006 Nov;135(4):190-9
MedlinePlus Health Information. consumer health - Bladder Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Classification of canine urinary bladder urothelial tumours based on the World Health Organization/International Society of Urological Pathology consensus classification.
  • One hundred canine urinary bladder urothelial (transitional cell) tumours, including roughly equal numbers of benign and malignant forms, were retrospectively categorized in accordance with the newly described human consensus classification of the World Health Organization/International Society of Urological Pathology (WHO/ISUP).
  • The tumours were reviewed and classified by three veterinary pathologists from Michigan State University and two human pathologists from the Armed Forces Institute of Pathology (AFIP).
  • Canine tumours, however, differed from human tumours in that the great majority showed extensive glandular differentiation (or metaplasia) and hyperplastic lesions tended to be more florid than those seen in human beings.
  • The various diagnoses and grades assigned to the tumours were highly consistent between all reviewing pathologists.
  • This paper presents the salient features of the new WHO and ISUP consensus classification and provides illustrations of the various tumour types that were directly applicable to the dog.
  • [MeSH-major] Dog Diseases / classification. Urinary Bladder Neoplasms / classification. Urinary Bladder Neoplasms / veterinary. Urothelium / pathology
  • [MeSH-minor] Animals. Consensus. Dogs. Humans. Neoplasm Staging. Retrospective Studies. World Health Organization

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17054974.001).
  • [ISSN] 0021-9975
  • [Journal-full-title] Journal of comparative pathology
  • [ISO-abbreviation] J. Comp. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  •  go-up   go-down


49. Mori Y, Maruyama T, Kondoh N, Nojima M, Yamamoto S, Shima H: [Orthotopic bladder substitution]. Hinyokika Kiyo; 2006 Jun;52(6):427-30

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Orthotopic bladder substitution].
  • Orthotopic bladder substitution is the most desired form of urinary diversion because the patient can restore normal voiding after cystectomy.
  • Each method of bladder substitution has merits and demerits.
  • We compared the Mainz method and the Studer method of orthotopic bladder substitution we performed on 8 and 11 patients, respectively since 1992.
  • The Studer orthotopic ileal bladder substitution has given better results with better voiding pattern and less complication rates.
  • We consider the Studer ileal bladder substitution as a good technique to restore normal voiding after cystectomy.
  • [MeSH-major] Ileum / surgery. Urinary Diversion / methods. Urinary Reservoirs, Continent

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16848355.001).
  • [ISSN] 0018-1994
  • [Journal-full-title] Hinyokika kiyo. Acta urologica Japonica
  • [ISO-abbreviation] Hinyokika Kiyo
  • [Language] jpn
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


50. Waine E, Stott M: Changing treatments for overactive bladder. Nurs Times; 2008 Oct 14-20;104(41):45-8
MedlinePlus Health Information. consumer health - Overactive Bladder.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Changing treatments for overactive bladder.
  • Overactive bladder is a common urological diagnosis which is often untreated as patients fail to seek help for this embarrassing problem.
  • Elizabeth Waine and Mark Stott summarise the symptoms and investigations for overactive bladder and provide an overview of the treatments available.
  • [MeSH-major] Urinary Bladder, Overactive / drug therapy. Urinary Incontinence, Urge / drug therapy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18979960.001).
  • [ISSN] 0954-7762
  • [Journal-full-title] Nursing times
  • [ISO-abbreviation] Nurs Times
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Muscarinic Antagonists; 0 / Neuromuscular Agents; 0 / Parasympatholytics; EC 3.4.24.69 / Botulinum Toxins, Type A
  • [Number-of-references] 20
  •  go-up   go-down


51. Yates DR, Rehman I, Meuth M, Cross SS, Hamdy FC, Catto JW: Methylational urinalysis: a prospective study of bladder cancer patients and age stratified benign controls. Oncogene; 2006 Mar 23;25(13):1984-8
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Methylational urinalysis: a prospective study of bladder cancer patients and age stratified benign controls.
  • Tumour suppressor gene (TSG) methylation has been proposed as a diagnostic marker for urothelial cancer (UC).
  • Here, we compare the frequency of urinary TSG methylation in young and elderly patients, with and without UC.
  • Urine samples were obtained prospectively from 35 UC patients, 35 benign controls over the age of 70 years and 34 healthy volunteers under the age of 40 years.
  • TSG methylation is detectable in urine DNA from patients with and without bladder cancer.
  • The lack of tumour specificity suggests that further investigation is required before this test is introduced into clinical practice.
  • [MeSH-major] Biomarkers, Tumor / urine. DNA Methylation. Genes, Tumor Suppressor. Urinary Bladder Neoplasms / genetics


52. Carballo Alvarez M, Martínez Vilariño M, Llaga Rodríguez M: [Bladder cleansing]. Rev Enferm; 2008 Jan;31(1):27-30
MedlinePlus Health Information. consumer health - Bladder Diseases.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Bladder cleansing].
  • [Transliterated title] Lavado vesical.
  • Bladder cleansings are administered in order to maintain the permeability of a probe and/or to eliminate an obstruction, be it a clot, urinary sand or detritus, by means of an infusion of intravenous fluid using sterile procedures through a bladder catheter.
  • This is a technique frequently used with patients undergoing genital-urinary surgery; it is not recommended for routine usage due to its high risk of associated infection.
  • Bladder cleansing can be continuous by means of a permanent bladder cleansing method or intermittent by means of an open or closed system.
  • [MeSH-major] Therapeutic Irrigation. Urinary Bladder Diseases / therapy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18497003.001).
  • [ISSN] 0210-5020
  • [Journal-full-title] Revista de enfermería (Barcelona, Spain)
  • [ISO-abbreviation] Rev Enferm
  • [Language] spa
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Spain
  •  go-up   go-down


53. Nerli RB, Kamat GV, Alur SS, Koura A, Prabha V, Amarkhed SS: Bladder exstrophy in adulthood. Indian J Urol; 2008 Apr;24(2):164-8

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Bladder exstrophy in adulthood.
  • BACKGROUND: We report our experience with the treatment of classic exstrophy of the bladder in a small series of seven adult males.
  • There are very few documented cases of adults presenting with exstrophy of bladder in literature.
  • MATERIALS AND METHODS: Adult males presenting with classic exstrophy of the bladder and complete epispadias underwent detailed evaluation including psychological assessment and counseling.
  • Prior to 2002 all patients underwent cystectomy of the existing bladder plate, with creation of catheterizable modified Mainz pouch.
  • Since 2002 patients were assessed for bladder reconstruction with augmentation ileocystoplasty, bladder neck reconstruction, and abdominal wall closure.
  • RESULTS: Seven adult males with classic exstrophy of the bladder and complete epispadias who had not received any previous treatment presented to us during the period 1991-2006.
  • Five of these underwent cystectomy with continent pouch and the remaining two underwent bladder reconstruction.
  • CONCLUSIONS: Surgical correction in adults with exstrophy of the bladder greatly improves self-esteem, confidence, and social relationship.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Urol Clin North Am. 1983 Aug;10(3):473-81 [6623735.001]
  • [Cites] Urology. 1973 Jul;2(1):20-4 [4148867.001]
  • [Cites] J Urol. 1966 Mar;95(3):356-9 [5906001.001]
  • [Cites] BJU Int. 2004 May;93(7):1037-42 [15142160.001]
  • [Cites] Urology. 2001 May;57(5):906-10 [11337291.001]
  • [Cites] J Urol. 2005 May;173(5):1728-31 [15821570.001]
  • [Cites] J Urol. 1999 Jun;161(6):1934-41 [10332476.001]
  • [Cites] J Urol. 1997 Mar;157(3):947-8 [9072609.001]
  • [Cites] Int Urol Nephrol. 1996;28(6):747-50 [9089040.001]
  • [Cites] J Urol. 1996 Dec;156(6):2037-40 [8911384.001]
  • [Cites] J Urol (Paris). 1992;98(1):64-5 [1527404.001]
  • [Cites] Teratology. 1987 Oct;36(2):221-7 [3424208.001]
  • [Cites] Urol Int. 1987;42(1):74-6 [3590408.001]
  • (PMID = 19468391.001).
  • [ISSN] 0970-1591
  • [Journal-full-title] Indian journal of urology : IJU : journal of the Urological Society of India
  • [ISO-abbreviation] Indian J Urol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] India
  • [Other-IDs] NLM/ PMC2684262
  • [Keywords] NOTNLM ; Adult / augmentation ileocystoplasty / bladder reconstruction / epispadias / exstrophy bladder
  •  go-up   go-down


54. Burks FN, Bui DT, Peters KM: Neuromodulation and the neurogenic bladder. Urol Clin North Am; 2010 Nov;37(4):559-65
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Neuromodulation and the neurogenic bladder.
  • Neurogenic bladder resulting from spinal cord injury and spina bifida has a profound impact on voiding function.
  • This article reviews the current literature with regards to electrical stimulation for neurogenic bladder and the clinical outcomes associated with sacral neuromodulation, pudendal neuromodulation, posterior tibial nerve stimulation, and the Finetech-Brindley posterior/anterior stimulator.
  • Neuromodulation, both electrical and physical, play an important role in the management of neurogenic bladder.
  • [MeSH-major] Electric Stimulation Therapy. Urinary Bladder, Neurogenic / therapy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010 Elsevier Inc. All rights reserved.
  • (PMID = 20955907.001).
  • [ISSN] 1558-318X
  • [Journal-full-title] The Urologic clinics of North America
  • [ISO-abbreviation] Urol. Clin. North Am.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  •  go-up   go-down


55. Drake MJ: The integrative physiology of the bladder. Ann R Coll Surg Engl; 2007 Sep;89(6):580-5
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The integrative physiology of the bladder.
  • Normal bladder function is complex, resulting from the co-operative interaction of numerous regulatory cell types, of which the interstitial cells and the peripheral neurones are particularly interesting.
  • Collectively, these comprise the myovesical plexus, which appears to confer structural and functional characteristics on the bladder loosely akin to those of the gut.
  • These include functional modularity, which gives rise to the potential for localised and propagating peristalsis-like movements in the bladder wall according to the prevailing physiological conditions.
  • Localised modular activity during filling may contribute to normal generation of sensation and exaggerated modular activity may give rise to urinary urgency.
  • Enhanced co-ordination of modular activity occurs in various models of detrusor overactivity; it leads to surges of contraction over a large part of the bladder wall, generating phasic changes in intravesical pressure.
  • During voiding, the myovesical plexus sustains detrusor contraction at the behest of the brainstem, monitoring state of bladder fullness as it does so, as a guide to the required duration for which it has to keep up the effort.
  • Accordingly, the bladder wall itself may house structures which render the bladder the effector level in a hierarchy of lower urinary tract regulation.
  • Dysfunction in these vital regulatory structures is an underestimated factor in the pathophysiology of clinical bladder problems.
  • [MeSH-major] Urinary Bladder / physiology. Urinary Bladder Diseases / physiopathology

  • MedlinePlus Health Information. consumer health - Bladder Diseases.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Lab Invest. 2000 Oct;80(10):1491-9 [11045565.001]
  • [Cites] BJU Int. 2006 Sep;98(3):643-50 [16925766.001]
  • [Cites] J Urol. 2002 Aug;168(2):832-6 [12131376.001]
  • [Cites] Exp Physiol. 2003 Jan;88(1):19-30 [12525852.001]
  • [Cites] J Urol. 2003 Apr;169(4):1573-6 [12629418.001]
  • [Cites] BJU Int. 2003 May;91(7):702-10 [12699489.001]
  • [Cites] Exp Physiol. 2003 May;88(3):343-57 [12719759.001]
  • [Cites] J Urol. 2003 Jul;170(1):276-9 [12796704.001]
  • [Cites] J Physiol. 2004 Sep 1;559(Pt 2):567-81 [15235094.001]
  • [Cites] Neurourol Urodyn. 1993;12(5):463-71 [8252050.001]
  • [Cites] J Anat. 1997 Jan;190 ( Pt 1):125-34 [9034888.001]
  • [Cites] BJU Int. 2005 May;95(7):1002-5 [15839921.001]
  • [Cites] J Urol. 2006 Feb;175(2):771-6 [16407048.001]
  • [Cites] BJU Int. 2006 Mar;97(3):612-6 [16469036.001]
  • [Cites] BJU Int. 2006 Jun;97(6):1332-7 [16686734.001]
  • [Cites] Auton Autacoid Pharmacol. 2006 Jul;26(3):253-60 [16879490.001]
  • [Cites] Auton Autacoid Pharmacol. 2006 Jul;26(3):261-6 [16879491.001]
  • [Cites] Lancet. 2001 Aug 4;358(9279):401-3 [11502339.001]
  • (PMID = 18201471.001).
  • [ISSN] 1478-7083
  • [Journal-full-title] Annals of the Royal College of Surgeons of England
  • [ISO-abbreviation] Ann R Coll Surg Engl
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Number-of-references] 19
  • [Other-IDs] NLM/ PMC2121225
  •  go-up   go-down


56. Freeman RM, Adekanmi OA: Overactive bladder. Best Pract Res Clin Obstet Gynaecol; 2005 Dec;19(6):829-41
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Overactive bladder.
  • The overactive bladder is a common condition, which has significant effects on quality of life.
  • Management includes excluding pathology and implementing behavioural changes such as caffeine reduction, bladder and pelvic floor training, as well as antimuscarinic drug therapy.
  • [MeSH-major] Urinary Bladder Diseases / physiopathology
  • [MeSH-minor] Behavior Therapy / methods. Cholinergic Antagonists / therapeutic use. Electric Stimulation Therapy / methods. Estrogens / therapeutic use. Female. Humans. Muscle Contraction. Patient Compliance. Pelvic Floor / physiopathology. Prevalence. Quality of Life. Risk Factors. Terminology as Topic. Urinary Incontinence / etiology. Urinary Incontinence / surgery

  • MedlinePlus Health Information. consumer health - Bladder Diseases.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16176887.001).
  • [ISSN] 1521-6934
  • [Journal-full-title] Best practice & research. Clinical obstetrics & gynaecology
  • [ISO-abbreviation] Best Pract Res Clin Obstet Gynaecol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Cholinergic Antagonists; 0 / Estrogens
  • [Number-of-references] 83
  •  go-up   go-down


57. Henderson E, Drake M: Overactive bladder. Maturitas; 2010 Jul;66(3):257-62
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Overactive bladder.
  • Overactive bladder is a condition whose prevalence increases with ageing, and which can substantially impair quality of life.
  • It is defined by presence of urinary urgency, in the absence of other causes of similar problems.
  • The underlying mechanisms are incompletely understood, but may include increased excitability of smooth muscle, abnormal spread of excitation through the bladder wall, increased sensory nerve activity, and altered processing of information in the central nervous system.
  • Initial treatment comprises fluid advice and bladder training, followed by drug prescription.
  • Neuromodulatory techniques (sacral or tibial nerve stimulation) and reconstructive surgery (augmentation cystoplasty, detrusor myectomy or urinary diversion) can be offered in severe cases, but can have inadequate outcomes and significant implications.
  • [MeSH-major] Urinary Bladder / physiopathology. Urinary Bladder, Overactive / therapy. Urinary Incontinence, Urge / therapy

  • MedlinePlus Health Information. consumer health - Overactive Bladder.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010 Elsevier Ireland Ltd. All rights reserved.
  • (PMID = 20399043.001).
  • [ISSN] 1873-4111
  • [Journal-full-title] Maturitas
  • [ISO-abbreviation] Maturitas
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Ireland
  • [Number-of-references] 54
  •  go-up   go-down


58. Tritschler S, Karl A, Sommer ML, Straub J, Strittmatter F, Tilki D, Hocaoglu Y, Stief C, Zaak D: Influence of clinical information on the interpretation of urinary cytology in bladder cancer: how suggestible is a cytologist? BJU Int; 2010 Oct;106(8):1165-8
MedlinePlus Health Information. consumer health - Bladder Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Influence of clinical information on the interpretation of urinary cytology in bladder cancer: how suggestible is a cytologist?
  • OBJECTIVE: to determine the influence of the knowledge of the endoscopic findings and the influence of the patient's history on the cytologist's judgement, as urinary cytology is known to be subjective and has several limitations, in particular a high inter- and intra-observer variability.
  • PATIENTS AND METHODS: we analysed the cytological and histological findings of patients who underwent transurethral resection of a bladder tumour, and determined whether the cytologist was aware of the endoscopic findings or not.
  • The sensitivity and specificity of cytology were calculated with or without this knowledge, and that of the patients' bladder cancer history.
  • RESULTS: the findings of 1705 patients were reviewed; in 641 the histological examination confirmed a malignant tumour and 1046 were classified as benign.
  • The specificity in patients with the endoscopic findings described as 'negative', 'inflammation', 'scar tissue', 'flat lesion', 'suspicious for tumour', and 'exophytic tumour' was 89.8%, 89.9%, 85.0%, 77.1%, 63.2% and 48.6%, respectively (P < 0.001).
  • In 898 patients the history was negative for bladder tumours.
  • Among these patients the sensitivity and specificity of cytology was 67.3% and 79.7%; the sensitivity and specificity was 65.4% and 74.8% for the 807 patients with a positive history of bladder cancer (P= 0.054).
  • CONCLUSION: both being aware of the endoscopic findings and a positive patient history for bladder cancer lowers the specificity of cytology.
  • [MeSH-major] Cell Biology. Clinical Competence / standards. Cystoscopy. Urinary Bladder / pathology. Urinary Bladder Neoplasms / pathology. Urology

  • Genetic Alliance. consumer health - Bladder cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20230393.001).
  • [ISSN] 1464-410X
  • [Journal-full-title] BJU international
  • [ISO-abbreviation] BJU Int.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


59. Nicola M, De Luca F: Bladder hernia. Arch Ital Urol Androl; 2006 Jun;78(2):77-8
MedlinePlus Health Information. consumer health - Bladder Diseases.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Bladder hernia.
  • Bladder hernia is a rare condition, but crural herniation of the bladder into the scrotum is very rare.
  • A case of bladder hernia presenting with urological symptoms is described.
  • A 71-year-old man presented to the urological ward complaining for persistent frequency and nocturia associated with loss offorce and decrease of caliber of the urinary stream and the presence of a large mass of the right scrotum.
  • An IVP (intra venous pyelography) showed a large herniation of the bladder through the right inguinal canal into the scrotum.
  • The hernia sac, containing bowel and bladder, was dissectedfreefrom the spermatic cord and the testis and the hernia defect was repaired.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16929610.001).
  • [ISSN] 1124-3562
  • [Journal-full-title] Archivio italiano di urologia, andrologia : organo ufficiale [di] Societa italiana di ecografia urologica e nefrologica
  • [ISO-abbreviation] Arch Ital Urol Androl
  • [Language] ENG
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Italy
  •  go-up   go-down


60. Radosavljević R, Hadzi Djokić J, Aćimović M, Pejcić T, Tulić C, Dzamić Z: [Morphologic characteristics of the urothelial bladder tumors]. Acta Chir Iugosl; 2007;54(4):101-4
MedlinePlus Health Information. consumer health - Bladder Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Morphologic characteristics of the urothelial bladder tumors].
  • Cancer of the urinary bladder is the fourth most common cancer in men and the ninth in women.
  • Approximately 67,000 people (50,000 males and 17,000 females) develop bladder cancer each year in the United States, and 13,750 individuals (9,630 males and 4,120 females) are expected to die from it.
  • In the showing of the morphologic characteristics of the tumors, authors underlining the increasing of the incidence, pathogenesis, premalignant lesions and the risk factors of disease.
  • [MeSH-major] Carcinoma, Transitional Cell / pathology. Urinary Bladder Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18595239.001).
  • [ISSN] 0354-950X
  • [Journal-full-title] Acta chirurgica Iugoslavica
  • [ISO-abbreviation] Acta Chir Iugosl
  • [Language] hrv
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Serbia
  •  go-up   go-down


61. Span PN, Witjes JA, Grebenchtchikov N, Geurts-Moespot A, Moonen PM, Aalders TW, Vriesema JL, Kiemeney LA, Schalken JA, Sweep FC: Components of the plasminogen activator system and their complexes in renal cell and bladder cancer: comparison between normal and matched cancerous tissues. BJU Int; 2008 Jul;102(2):177-82
MedlinePlus Health Information. consumer health - Kidney Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Components of the plasminogen activator system and their complexes in renal cell and bladder cancer: comparison between normal and matched cancerous tissues.
  • OBJECTIVE: To analyse and compare the concentration of plasminogen activator (PA), urokinase-type PA (uPA), tissue-type PA (tPA), PA inhibitor (PAI)-1 and PAI-2, and the complexes uPA-PAI-1 and tPA-PAI-1 and calculated uPA and tPA uncomplexed with PAI-1 ('free') in urothelial cell carcinoma and matched benign urothelium, and in renal cell carcinoma (RCC) and matched benign renal tissue.
  • RESULTS: Tissue levels of uPA-PAI-1 and tPA-PAI-1, but also PAI-1 itself, were greater in tumorous bladder and kidney tissue than in matched normal tissue (by 1.5-7.8 times).
  • Free tPA was clearly lower in tumour tissue (by 0-0.12-fold).
  • In bladder cancer, but not in RCC, levels of uPA (15.8-fold) and free uPA (16.4-fold) were greater in tumour tissue.
  • For both normal bladder and kidney tissue, there was no clear correlation between uPA-PAI-1 complex and either component.
  • However, the formation of tPA-PAI-1 complexes in normal bladder and kidney tissue was primarily determined by PAI-1.
  • Interestingly, in tumour tissues there was a strong, significant correlation between complex levels and both components.
  • CONCLUSION: RCC and bladder cancer show distinct profiles of components of the PA system.
  • This study provides a basis for further studies into both the (patho)physiological role of the PA system in these tumours, and into a possible relation with tumour progression and prognosis, and as target for therapy.
  • [MeSH-major] Biomarkers, Tumor / metabolism. Carcinoma, Renal Cell / pathology. Kidney Neoplasms / pathology. Plasminogen Activators / metabolism. Urinary Bladder Neoplasms / pathology

  • Genetic Alliance. consumer health - Kidney cancer.
  • Genetic Alliance. consumer health - Bladder cancer.
  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18336603.001).
  • [ISSN] 1464-410X
  • [Journal-full-title] BJU international
  • [ISO-abbreviation] BJU Int.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; EC 3.4.21.- / Plasminogen Activators
  •  go-up   go-down


62. Yoshimura R, Adachi T, Funao K, Kobayakawa H, Matsuyama M, Tsuchida K, Takemoto Y, Nakatani T: Treatment of bladder tumors and benign prostatic hyperplasia with a new TUR system using physiological saline as perfusate. World J Surg; 2006 Mar;30(3):473-7
Hazardous Substances Data Bank. SODIUM CHLORIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Treatment of bladder tumors and benign prostatic hyperplasia with a new TUR system using physiological saline as perfusate.
  • We have treated both bladder tumor and benign prostatic hyperplasia cases with this new system.
  • When physiological saline is used as the perfusate, blood electrolyte levels are not greatly changed, even after extensive resection of the bladder wall; as a result, this new system is also cost effective because physiological saline is less expensive than non-electroconductive solutions and requires no counter-electrode.
  • [MeSH-major] Prostatic Hyperplasia / surgery. Sodium Chloride / administration & dosage. Transurethral Resection of Prostate / methods. Urinary Bladder Neoplasms / surgery


63. Pascual Mateo C, Nieto Gallego MA, Rodríguez García N, Luján Galán M, Berenguer Sánchez A: [Idiopathic local bladder amyloidosis]. Arch Esp Urol; 2005 Apr;58(3):253-5
MedlinePlus Health Information. consumer health - Bladder Diseases.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Idiopathic local bladder amyloidosis].
  • [Transliterated title] Amiloidosis vesical primaria localizada idiopática.
  • OBJECTIVE: To report one case of primary bladder amyloidosis.
  • RESULTS: Pathologic features were consistent with amyloidosis of the bladder wall.
  • CONCLUSIONS: Local idiopathic bladder amyloidosis is a very rare disease and the most common presenting symptom is painless hematuria.
  • It may be difficult to differentiate between this disease and a urothelial bladder neoplasia.
  • [MeSH-major] Amyloidosis / pathology. Urinary Bladder Diseases / pathology

  • Genetic Alliance. consumer health - Amyloidosis.
  • MedlinePlus Health Information. consumer health - Amyloidosis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15906621.001).
  • [ISSN] 0004-0614
  • [Journal-full-title] Archivos españoles de urología
  • [ISO-abbreviation] Arch. Esp. Urol.
  • [Language] spa
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Spain
  •  go-up   go-down


64. Knüchel R, Lindemann-Docter K: [Urine-based tumour diagnostics for bladder cancer: effects of the new histopathological classification--food for thought]. Urologe A; 2009 Jun;48(6):598-608
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Urine-based tumour diagnostics for bladder cancer: effects of the new histopathological classification--food for thought].
  • [Transliterated title] Urinbasierte Tumordiagnostik des Harnblasenkarzinoms: Auswirkungen der neuen histopathologischen Klassifikation--ein Denkanstoss.
  • The new WHO classification of bladder cancer was published in 2004 and consequently cannot be regarded as very recent.
  • However, it is still timely since it picks up considerations affecting other schemes of tumour classification as well.
  • The WHO classification of 2004 does not include cytological diagnosis.
  • Thinking about and considering tumour tissue diagnosis, the style of cytological diagnoses is also affected.
  • For tissue diagnoses, low- and high-grade tumours are differentiated from benign lesions including reactive changes.
  • The element of this classification which has to be transferred to cytology is especially the unequivocal diagnosis of high-grade lesions.
  • The low-grade lesion, correlating with tissue of well-differentiated papillary tumours and dysplasias, mostly cannot be distinguished cytologically with certainty from a broad spectrum of non-malignant lesions (papillomas, reactive urothelial detachment in urolithiasis patients, cytology specimen from vigorously irrigated bladders).
  • For the latter group our aim should be to establish an additional diagnostic tool of high quality driven by clinical questions (e.g. potential of tumour progression).
  • [MeSH-major] Medical Oncology / trends. Urinalysis / trends. Urinary Bladder Neoplasms / diagnosis. Urinary Bladder Neoplasms / urine

  • Genetic Alliance. consumer health - Bladder cancer.
  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • MedlinePlus Health Information. consumer health - Urinalysis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Clin Pathol. 2001 Jul;116(1):79-86 [11447756.001]
  • [Cites] Urologe A. 2009 Jun;48(6):619-24 [19557467.001]
  • [Cites] Urologe A. 2008 May;47(5):627-36; quiz 637 [18427766.001]
  • [Cites] Am J Surg Pathol. 1999 Apr;23(4):443-7 [10199474.001]
  • [Cites] Expert Rev Mol Diagn. 2007 Jan;7(1):11-9 [17187480.001]
  • [Cites] J Urol. 2006 Dec;176(6 Pt 1):2343-6 [17085097.001]
  • [Cites] Am J Clin Pathol. 2006 Aug;126(2):294-301 [16891206.001]
  • [Cites] Scand J Urol Nephrol. 2008;42(2):175; author reply 176 [18365925.001]
  • (PMID = 19557464.001).
  • [ISSN] 1433-0563
  • [Journal-full-title] Der Urologe. Ausg. A
  • [ISO-abbreviation] Urologe A
  • [Language] ger
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Germany
  • [Number-of-references] 12
  •  go-up   go-down


65. Boyle H, Fléchon A, Droz JP: [Uncommon bladder tumours]. Bull Cancer; 2010;97 Suppl Cancer de la vessie:51-7
MedlinePlus Health Information. consumer health - Bladder Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Uncommon bladder tumours].
  • [Transliterated title] Tumeurs rares de la vessie.
  • Bladder tumours are frequent with around 10,000 new cases each year in France.
  • These tumours are possibly secondary to alkylating drug metabolites or pelvic radiotherapy and they have often a poor prognostic outcome.
  • This is also the case of spindle cell carcinoma, an endocrine variant of rare bladder cancers.
  • Other tumours have a more locally invasive pattern, as have urachal adenocarcinomas, sarcomas.
  • The treatment is based on aggressive surgical exeresis of the tumour and surrounding structures.
  • [MeSH-major] Urinary Bladder Neoplasms

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20534390.001).
  • [ISSN] 1769-6917
  • [Journal-full-title] Bulletin du cancer
  • [ISO-abbreviation] Bull Cancer
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] France
  •  go-up   go-down


66. Birder LA: TRPs in bladder diseases. Biochim Biophys Acta; 2007 Aug;1772(8):879-84
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] TRPs in bladder diseases.
  • This review attempts to provide an overview of the current knowledge of TRP proteins and their possible role in bladder function and disease.
  • Of those belonging to the group 1 subfamily, a number of TRPV, TRPM and TRPA proteins associated with osmoregulation, thermal, chemical and mechanical signaling mechanisms have been shown to be expressed within the lower urinary tract.
  • Though the biological role of many of these channels in urinary bladder function still remains elusive, TRPV1 is by far the best characterized and is thought to be involved in a number of bladder disorders [A.

  • MedlinePlus Health Information. consumer health - Bladder Diseases.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Nature. 1997 Oct 23;389(6653):816-24 [9349813.001]
  • [Cites] Urology. 1997 Dec;50(6A Suppl):36-52; discussion 53-6 [9426749.001]
  • [Cites] Pharmacol Ther. 2005 May;106(2):179-208 [15866319.001]
  • [Cites] Neurosci Lett. 2005 Jun 10-17;381(1-2):42-6 [15882787.001]
  • [Cites] J Urol. 1999 Dec;162(6):1890-6 [10569531.001]
  • [Cites] Proc Natl Acad Sci U S A. 2000 May 23;97(11):6155-60 [10823958.001]
  • [Cites] Am J Physiol Renal Physiol. 2000 Jun;278(6):F867-74 [10836974.001]
  • [Cites] Proc Natl Acad Sci U S A. 2000 Jul 5;97(14):8134-9 [10859346.001]
  • [Cites] J Urol. 2000 Sep;164(3 Pt 1):676-9 [10953124.001]
  • [Cites] Nature. 2000 Dec 21-28;408(6815):985-90 [11140687.001]
  • [Cites] Regul Pept. 2001 Sep 15;101(1-3):1-18 [11495674.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Nov 6;98(23):13396-401 [11606761.001]
  • [Cites] Cell. 2002 Mar 8;108(5):705-15 [11893340.001]
  • [Cites] Neuroscience. 2002;109(4):787-98 [11927161.001]
  • [Cites] J Urol. 2002 Jul;168(1):293-7 [12050559.001]
  • [Cites] Science. 2002 Jun 14;296(5575):2046-9 [12016205.001]
  • [Cites] J Physiol. 2002 Aug 15;543(Pt 1):211-20 [12181293.001]
  • [Cites] Nat Neurosci. 2002 Sep;5(9):856-60 [12161756.001]
  • [Cites] Urology. 2003 Nov;62(5):909-13 [14624918.001]
  • [Cites] J Urol. 2004 Feb;171(2 Pt 1):938-43 [14713858.001]
  • [Cites] Urol Int. 2004;72(2):145-9 [14963356.001]
  • [Cites] J Biol Chem. 2004 Feb 20;279(8):7048-54 [14630912.001]
  • [Cites] BJU Int. 2004 Apr;93(6):770-6 [15049988.001]
  • [Cites] J Urol. 2004 Jun;171(6 Pt 1):2492-6 [15126883.001]
  • [Cites] Eur Urol. 2004 Jul;46(1):88-93; discussion 93-4 [15183552.001]
  • [Cites] J Urol. 2005 Sep;174(3):818 [16093961.001]
  • [Cites] J Urol. 2005 Sep;174(3):977-82; discussion 982-3 [16094018.001]
  • [Cites] J Physiol. 2005 Aug 15;567(Pt 1):53-8 [15961428.001]
  • [Cites] Eur J Neurosci. 2005 Aug;22(4):825-34 [16115206.001]
  • [Cites] Br J Urol. 1997 Dec;80(6):845-52 [9439395.001]
  • [Cites] J Urol. 1998 Jul;160(1):34-8 [9628600.001]
  • [Cites] Neurourol Urodyn. 1998;17(5):513-23 [9776014.001]
  • [Cites] World J Urol. 1999 Apr;17(2):126-30 [10367373.001]
  • [Cites] J Urol. 1999 Jul;162(1):3-11 [10379728.001]
  • [Cites] Am J Physiol. 1999 Sep;277(3 Pt 2):R786-94 [10484496.001]
  • [Cites] Urology. 2005 Feb;65(2):400-5 [15708075.001]
  • [Cites] J Cell Sci. 2005 Mar 1;118(Pt 5):917-28 [15713749.001]
  • [Cites] J Urol. 2005 May;173(5):1590-4 [15821499.001]
  • [Cites] Pflugers Arch. 2005 Oct;451(1):160-7 [15952037.001]
  • [Cites] Nat Clin Pract Urol. 2004 Dec;1(2):85-9 [16474520.001]
  • [Cites] Nat Clin Pract Urol. 2005 Oct;2(10):492-501 [16474623.001]
  • [Cites] Nat Clin Pract Urol. 2005 Nov;2(11):546-54 [16474598.001]
  • [Cites] J Neurosci. 2006 Apr 5;26(14):3864-74 [16597741.001]
  • [Cites] Endocr Relat Cancer. 2006 Mar;13(1):27-38 [16601277.001]
  • [Cites] J Urol. 2006 Jun;175(6):2341-4 [16697870.001]
  • [Cites] Biochem Pharmacol. 2006 Jun 28;72(1):104-14 [16725114.001]
  • [Cites] J Urol. 2006 Aug;176(2):797-801 [16813950.001]
  • [Cites] Naunyn Schmiedebergs Arch Pharmacol. 2006 Jul;373(4):287-99 [16721555.001]
  • [Cites] Mol Cell Neurosci. 2006 Aug;32(4):335-43 [16829128.001]
  • [Cites] Neurogastroenterol Motil. 2006 Aug;18(8):590-4 [16918723.001]
  • [Cites] Trends Mol Med. 2006 Nov;12(11):545-54 [16996800.001]
  • [Cites] Eur Urol. 2006 Dec;50(6):1299-305 [16697519.001]
  • [Cites] Nat Clin Pract Urol. 2007 Jan;4(1):46-54 [17211425.001]
  • [Cites] Cell Calcium. 2007 Mar;41(3):285-94 [16949669.001]
  • [Cites] Biochim Biophys Acta. 2007 Aug;1772(8):989-1003 [17321113.001]
  • [Cites] J Urol. 2004 Sep;172(3):1175-8 [15311065.001]
  • [Cites] Eur J Pharmacol. 2004 Oct 1;500(1-3):351-69 [15464045.001]
  • [Cites] J Urol. 1989 Jul;142(1):150-4 [2733095.001]
  • [Cites] J Auton Nerv Syst. 1990 Jul;30 Suppl:S71-7 [2212495.001]
  • [Cites] Ciba Found Symp. 1990;151:77-83; discussion 83-90 [2226067.001]
  • [Cites] Lancet. 1992 May 16;339(8803):1239 [1349978.001]
  • [Cites] Life Sci. 1993;52(20):PL221-6 [8483387.001]
  • [Cites] Brain Res. 1995 Apr 24;678(1-2):40-8 [7620897.001]
  • [Cites] J Urol. 1995 Nov;154(5):1825-9 [7563356.001]
  • [Cites] J Urol. 1997 Feb;157(2):585-9 [8996364.001]
  • [Cites] Am J Physiol. 1997 Apr;272(4 Pt 2):R1271-82 [9140030.001]
  • (PMID = 17560087.001).
  • [ISSN] 0006-3002
  • [Journal-full-title] Biochimica et biophysica acta
  • [ISO-abbreviation] Biochim. Biophys. Acta
  • [Language] ENG
  • [Grant] United States / NIDDK NIH HHS / DK / R01 DK57284; United States / NIDDK NIH HHS / DK / R01 DK54824; United States / NIDDK NIH HHS / DK / R01 DK057284-10; United States / NIDDK NIH HHS / DK / R37 DK054824-13; United States / NIDDK NIH HHS / DK / R01 DK057284; United States / NIDDK NIH HHS / DK / R37 DK054824-12; United States / NIDDK NIH HHS / DK / R01 DK057284-11; United States / NIDDK NIH HHS / DK / R37 DK054824; United States / NIDDK NIH HHS / DK / R56 DK057284; United States / NIDDK NIH HHS / DK / R01 DK054824
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Review
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Transient Receptor Potential Channels
  • [Number-of-references] 74
  • [Other-IDs] NLM/ NIHMS243025; NLM/ PMC3713460
  •  go-up   go-down


67. Kanematsu A, Yamamoto S, Ogawa O: Changing concepts of bladder regeneration. Int J Urol; 2007 Aug;14(8):673-8
MedlinePlus Health Information. consumer health - Bladder Diseases.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Changing concepts of bladder regeneration.
  • During the last decade, there has been a dramatic increase in studies aimed at regeneration of the urinary bladder.
  • Many studies employed animal-derived or synthetic materials as grafts for experimental bladder augmentation models, with or without additional measures to promote regeneration, such as autologous cell transplantation or growth factor loading.
  • One major problem in these studies is the lack of a clear distinction between native and regenerated bladder in total bladder function after augmentation.
  • In contrast, researchers have recently attempted to establish alternative regenerative strategies for treating bladder diseases, and have employed far more diverse approaches according to the various pathological conditions to be treated.
  • For total replacement of the bladder after cystectomy for invasive bladder cancer, urothelium-covered neobladder with non-urinary tract backbone remains a viable choice.
  • In addition, functional bladder diseases such as urinary incontinence, weak detrusor, or non-compliant fibrotic bladder have also been major targets for many leading research groups in this field.
  • Such altered research direction would inevitably lead to less surgically based basic biological research, and also would include a far wider spectrum of adult and pediatric bladder diseases, from overactive bladder to dysfunctional voiding.
  • [MeSH-major] Regeneration. Urinary Bladder / physiology. Urinary Bladder Diseases / physiopathology. Urinary Bladder Diseases / therapy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17681053.001).
  • [ISSN] 0919-8172
  • [Journal-full-title] International journal of urology : official journal of the Japanese Urological Association
  • [ISO-abbreviation] Int. J. Urol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Australia
  • [Number-of-references] 65
  •  go-up   go-down


68. Siddiqui EJ, Shabbir M, Thompson CS, Mumtaz FH, Mikhailidis DP: Growth inhibitory effect of doxazosin on prostate and bladder cancer cells. Is the serotonin receptor pathway involved? Anticancer Res; 2005 Nov-Dec;25(6B):4281-6
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Growth inhibitory effect of doxazosin on prostate and bladder cancer cells. Is the serotonin receptor pathway involved?
  • Doxazosin, an alpha1-adrenoceptor antagonist, is used for the treatment of benign prostatic hyperplasia (BPH) and hypertension.
  • The effect of doxazosin on the growth of prostate and bladder cancer cell lines was assessed and whether the growth inhibitory effect of doxazosin on prostate cancer cells is serotonin (5-hydroxtryptamine; 5HT)-dependent was investigated.
  • CONCLUSION: Doxazosin significantly inhibited prostate (PC3) and bladder cancer (HT1376) cell growth.
  • The effect of alpha1-adrenoceptor antagonists on tumour cell growth merits further investigation.
  • [MeSH-major] Adrenergic alpha-Antagonists / pharmacology. Carcinoma, Transitional Cell / drug therapy. Doxazosin / pharmacology. Prostatic Neoplasms / drug therapy. Receptor, Serotonin, 5-HT1B / metabolism. Serotonin / pharmacology. Urinary Bladder Neoplasms / drug therapy

  • Genetic Alliance. consumer health - Bladder cancer.
  • Genetic Alliance. consumer health - Prostate cancer.
  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. DOXAZOSIN MESYLATE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16309229.001).
  • [ISSN] 0250-7005
  • [Journal-full-title] Anticancer research
  • [ISO-abbreviation] Anticancer Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Adrenergic alpha-1 Receptor Antagonists; 0 / Adrenergic alpha-Antagonists; 0 / Pyridines; 0 / Pyrroles; 0 / Receptor, Serotonin, 5-HT1B; 0 / Serotonin 5-HT1 Receptor Agonists; 127792-75-0 / 3-(1,2,5,6-tetrahydropyrid-4-yl)pyrrolo(3,2-b)pyrid-5-one; 333DO1RDJY / Serotonin; NW1291F1W8 / Doxazosin
  •  go-up   go-down


69. Griffiths D: Imaging bladder sensations. Neurourol Urodyn; 2007 Oct;26(6 Suppl):899-903
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Imaging bladder sensations.
  • Normal bladder sensations progress in a continuum of gradually increasing intensity and unpleasantness, from first sensation of bladder filling, through first desire to void, to strong desire to void.
  • The abnormal sensation of urgency is not part of this continuum and is one of the defining symptoms of the overactive bladder (OAB) syndrome.
  • We have imaged these cerebral responses in female volunteers, either with normal bladder control or with urge incontinence (poor control).
  • Normal bladder filling sensations are mapped mainly in the insula, shifting anteriorly as sensation becomes stronger and more unpleasant.
  • In subjects with poor bladder control, sensations and brain responses are different from normal.
  • Responses are relatively small at low bladder volumes (with mild sensation), but become exaggerated (with strong sensation) above a certain volume threshold, even when there is no actual detrusor overactivity.
  • Based on these results, it is unlikely that abnormal (OAB) responses to bladder filling can be accounted for simply by increased bladder afferent activity, that is, bladder hypersensitivity.
  • [MeSH-major] Brain / physiology. Magnetic Resonance Imaging. Sensation / physiology. Urinary Bladder / innervation. Urinary Incontinence, Urge / physiopathology

  • MedlinePlus Health Information. consumer health - MRI Scans.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2007 Wiley-Liss, Inc.
  • (PMID = 17654564.001).
  • [ISSN] 0733-2467
  • [Journal-full-title] Neurourology and urodynamics
  • [ISO-abbreviation] Neurourol. Urodyn.
  • [Language] eng
  • [Grant] United States / NIA NIH HHS / AG / R01-AG020629; United States / NIA NIH HHS / AG / R03-AG25166
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] United States
  • [Number-of-references] 7
  •  go-up   go-down


70. O'Hanlan KA: Cystosufflation to prevent bladder injury. J Minim Invasive Gynecol; 2009 Mar-Apr;16(2):195-7
Hazardous Substances Data Bank. Carbon dioxide .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cystosufflation to prevent bladder injury.
  • STUDY OBJECTIVE: This brief report will share information about the use and safety of inflating the bladder with carbon dioxide to delineate the margins during laparoscopic dissections near the bladder in patients who have scarring, adhesions, or challenging anatomy.
  • Indications included finding of adhesions from earlier cesarean section or massive myomas obscuring bladder margins, or planned anterior colpopexy or vaginal sacrocolpopexy.
  • INTERVENTIONS: Cystosufflation uniformly entailed the following: clamping of the bladder catheter with a Kelly clamp; connection of the laparoscopic carbon-dioxide insufflation tubing to the catheter; then under direct laparoscopic observation, release of the Kelly clamp with immediate bladder inflation revealing the cystic margins.
  • MEASUREMENTS AND MAIN RESULTS: Cystosufflation safely facilitated the dissection of the bladder off the anterior cervix and vagina, or off the anterior abdominal wall.
  • Distention of the bladder elevated and rounded up the bladder margins so that the muscularis could be clearly identified, preventing bladder injury in all patients.
  • [MeSH-major] Carbon Dioxide. Hysterectomy / methods. Insufflation / methods. Intraoperative Complications / prevention & control. Laparoscopy / methods. Urinary Bladder / injuries

  • MedlinePlus Health Information. consumer health - Hysterectomy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19138575.001).
  • [ISSN] 1553-4650
  • [Journal-full-title] Journal of minimally invasive gynecology
  • [ISO-abbreviation] J Minim Invasive Gynecol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 142M471B3J / Carbon Dioxide
  •  go-up   go-down


71. Carr LK: Overactive bladder. Can J Urol; 2008 Aug;15 Suppl 1:32-6; discussion 36
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Overactive bladder.
  • Overactive bladder (OAB) is a common condition (prevalence 14%-18% of Canadians) and has a significant negative impact on quality of life.
  • OAB may be idiopathic or may occur with other common conditions such as bladder outlet obstruction, neurological disease, or stress incontinence.
  • [MeSH-major] Urinary Bladder, Overactive
  • [MeSH-minor] Behavior Therapy / methods. Canada / epidemiology. Diagnosis, Differential. Humans. Muscarinic Antagonists / therapeutic use. Neuromuscular Agents / therapeutic use. Prevalence. Prognosis. Urodynamics

  • MedlinePlus Health Information. consumer health - Overactive Bladder.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18700063.001).
  • [ISSN] 1195-9479
  • [Journal-full-title] The Canadian journal of urology
  • [ISO-abbreviation] Can J Urol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Canada
  • [Chemical-registry-number] 0 / Muscarinic Antagonists; 0 / Neuromuscular Agents
  • [Number-of-references] 21
  •  go-up   go-down


72. Leung UC, Wong PY, Roberts RH, Koea JB: Gall bladder polyps in sclerosing cholangitis: does the 1-cm rule apply? ANZ J Surg; 2007 May;77(5):355-7
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Gall bladder polyps in sclerosing cholangitis: does the 1-cm rule apply?
  • INTRODUCTION: Polyps of the gall bladder (PLG) are common findings in radiological investigations of the gall bladder and most are benign although carcinoma of the gall bladder can arise in PLG.
  • METHODS: All patients undergoing surgical resection for gall bladder cancer were entered into a prospective database.
  • Four patients with primary sclerosing cholangitis (PSC) presenting with gall bladder cancer in a PLG are studied.
  • Tumour markers carcinoembryonic antigen and CA19-9 were within the normal range in all patients.
  • Two patients with T1 tumours remain alive and well at 2 and 4 years post-cholecystectomy.
  • Of the remaining two patients with T2 tumours, one underwent re-resection of the liver bed and portal lymph nodes and remains alive and well at 12 months.
  • CONCLUSION: Gall bladder polyps, which are common and are usually benign in the general population, are often malignant in PSC.
  • [MeSH-major] Carcinoma / diagnosis. Cholangitis, Sclerosing / complications. Gallbladder Diseases / radiography. Gallbladder Neoplasms / diagnosis. Polyps / radiography

  • MedlinePlus Health Information. consumer health - Gallbladder Cancer.
  • MedlinePlus Health Information. consumer health - Gallbladder Diseases.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17497975.001).
  • [ISSN] 1445-1433
  • [Journal-full-title] ANZ journal of surgery
  • [ISO-abbreviation] ANZ J Surg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Australia
  •  go-up   go-down


73. Solifenacin and darifenacin for overactive bladder. Med Lett Drugs Ther; 2005 Mar 14;47(1204):23-4
MedlinePlus Health Information. consumer health - Urinary Incontinence.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Solifenacin and darifenacin for overactive bladder.
  • Darifenacin (Enablex) and solifenacin (VESIcare) are 2 new oral anticholinergics available for once-daily symptomatic treatment of overactive bladder.
  • Overactive bladder is a common condition in older patients.
  • In some experimental studies, the new drugs particularly target bladder receptors, but the clinical significance of these findings is unknown.
  • [MeSH-major] Benzofurans / therapeutic use. Pyrrolidines / therapeutic use. Quinuclidines / therapeutic use. Tetrahydroisoquinolines / therapeutic use. Urinary Incontinence / drug therapy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15767976.001).
  • [ISSN] 0025-732X
  • [Journal-full-title] The Medical letter on drugs and therapeutics
  • [ISO-abbreviation] Med Lett Drugs Ther
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Benzofurans; 0 / Pyrrolidines; 0 / Quinuclidines; 0 / Tetrahydroisoquinolines; APG9819VLM / darifenacin; KKA5DLD701 / Solifenacin Succinate
  •  go-up   go-down


74. Gargollo PC, Borer JG: Contemporary outcomes in bladder exstrophy. Curr Opin Urol; 2007 Jul;17(4):272-80
MedlinePlus Health Information. consumer health - Urinary Incontinence.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Contemporary outcomes in bladder exstrophy.
  • PURPOSE OF REVIEW: The patient with bladder exstrophy presents complex surgical and clinical management challenges to the pediatric urologist.
  • RECENT FINDINGS: Most of the early literature pertaining to bladder exstrophy has focused on surgical techniques and management.
  • Psychosexual development, sexual function and social adaptation have received as much attention as urinary continence status, bladder, and renal function.
  • SUMMARY: Despite the complex nature of bladder exstrophy, there are no well designed, prospective trials examining clinical outcomes in these patients.
  • Until better trials are planned, executed and published, much of what we know about patients with bladder exstrophy will be based on retrospective observations with significant biases.
  • [MeSH-major] Bladder Exstrophy / psychology. Bladder Exstrophy / surgery. Urinary Incontinence / psychology. Urinary Incontinence / surgery. Urologic Surgical Procedures / methods

  • Genetic Alliance. consumer health - Exstrophy of the Bladder.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17558272.001).
  • [ISSN] 0963-0643
  • [Journal-full-title] Current opinion in urology
  • [ISO-abbreviation] Curr Opin Urol
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 63
  •  go-up   go-down


75. Spahn M, Bader P, Westermann D, Echtle D, Frohneberg D: Bladder carcinoma during pregnancy. Urol Int; 2005;74(2):153-9
MedlinePlus Health Information. consumer health - Tumors and Pregnancy.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Bladder carcinoma during pregnancy.
  • INTRODUCTION: We report 3 cases of bladder cancer during pregnancy and give a review of the literature in an attempt to evaluate tumor at presentation, characteristics, maternal and fetal outcome.
  • MATERIALS AND METHODS: The case history of 3 pregnant women treated for bladder cancer in 2001 together with the results of a MEDLINE search from 1966 to 2003.
  • RESULTS: Out of 27 cases of nonbilharzial bladder carcinoma, 74% presented with transitional cell carcinoma.
  • Five patients had muscle-invasive tumors.
  • Only half of the tumors were identified by ultrasonography.
  • Although superficial bladder carcinoma was transurethrally resected alone, outcome and prognosis are good.
  • But the prognosis of locally advanced bladder carcinoma is poor.
  • CONCLUSION: Any doubtful genital bleeding during pregnancy without definite proof of vaginal/cervical origin should be investigated by both ultrasonography of the upper urinary tract and urethrocystoscopy.
  • Superficial bladder tumors can be most effectively treated by transurethral resection followed by cystoscopy, whereas the prognosis of muscle-invasive bladder carcinoma is poor and demands more radical treatment, depending on the stage of pregnancy.
  • [MeSH-major] Carcinoma, Transitional Cell. Pregnancy Complications, Neoplastic. Urinary Bladder Neoplasms

  • Genetic Alliance. consumer health - Pregnancy.
  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15756068.001).
  • [ISSN] 0042-1138
  • [Journal-full-title] Urologia internationalis
  • [ISO-abbreviation] Urol. Int.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Switzerland
  • [Number-of-references] 34
  •  go-up   go-down


76. Allen D, Glass J: Transvaginal contraception--avoid the bladder. Int J Clin Pract Suppl; 2005 Apr;(147):87-8
MedlinePlus Health Information. consumer health - Foreign Bodies.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Transvaginal contraception--avoid the bladder.
  • We report two cases of female contraceptive methods, resulting in urological presentation, with bladder foreign bodies.
  • History, mode of diagnosis and surgical extraction technique differed in both patients.
  • A second patient, with recurrent urinary tract infections, was found to have an intrauterine contraceptive device (IUCD) in her bladder on ultrasound.
  • Attempts to remove it endoscopically failed, and an, open procedure was required to free the IUCD from the bladder sidewall.
  • [MeSH-major] Foreign Bodies / etiology. Intrauterine Devices / adverse effects. Natural Family Planning Methods / adverse effects. Urinary Bladder
  • [MeSH-minor] Adult. Female. Humans. Thermometers. Urinary Tract Infections / etiology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15875635.001).
  • [ISSN] 1368-504X
  • [Journal-full-title] International journal of clinical practice. Supplement
  • [ISO-abbreviation] Int J Clin Pract Suppl
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  •  go-up   go-down


77. Fumadó Ciutat L, Rodríguez Tolrà J, Pastor López S, Riera Canals L, Franco Miranda E: [Massive bladder hernia]. Arch Esp Urol; 2005 Dec;58(10):1078-80
MedlinePlus Health Information. consumer health - Bladder Diseases.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Massive bladder hernia].
  • [Transliterated title] Hernia vesical masiva.
  • OBJECTIVES: We report a case of a huge bladder hernia conditioning the migration of almost all the bladder into the scrotum.
  • METHODS AND RESULTS: 65-year-old male being studied for BPH who presents a scrotal tumor, which turned out to be a huge inguinal bladder hernia in scrotum, paraperitoneal, accompanied by an inguinal hernia.
  • The treatment consisted in bladder resection and repair of the inguinal hernia with a marlex mesh.
  • CONCLUSIONS: Bladder hernia is an uncommon pathology, and in most of the cases it is an incidental finding during the repair of an inguinal hernia.
  • The diagnosis is clinical, but comfirmation can be done by retrograde cystoghraphy, ultrasonography or CT The treatment is surgical, repairing the herniation or adding the resection of the bladder herniation.
  • [MeSH-major] Hernia, Inguinal / etiology. Urinary Bladder Diseases / complications

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16482863.001).
  • [ISSN] 0004-0614
  • [Journal-full-title] Archivos españoles de urología
  • [ISO-abbreviation] Arch. Esp. Urol.
  • [Language] spa
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Spain
  •  go-up   go-down


78. Foon R, Drake MJ: The overactive bladder. Ther Adv Urol; 2010 Aug;2(4):147-55

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The overactive bladder.
  • Urinary urgency and the associated symptoms which comprise overactive bladder are prevalent amongst the general population and adversely affect quality of life.
  • Disease management consists of a sequential series of options starting with behavioural and lifestyle techniques, pharmacological management (antimuscarinics) and, in severe cases, surgical treatment (urinary diversion, neuromodulation, augmentation cystoplasty and detrusor myectomy).
  • The hierarchy of the central nervous system control adds additional complexity to understanding the oflower urinary tract function.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Urol Int. 2004;72(2):145-9 [14963356.001]
  • [Cites] J Physiol. 2004 Sep 1;559(Pt 2):567-81 [15235094.001]
  • [Cites] J Urol. 2004 Aug;172(2):748-52 [15247775.001]
  • [Cites] Neurochem Int. 2004 Dec;45(7):987-93 [15337297.001]
  • [Cites] J Urol. 2005 Sep;174(3):977-82; discussion 982-3 [16094018.001]
  • [Cites] J Physiol. 2006 Jan 1;570(Pt 1):13-22 [16210349.001]
  • [Cites] BJU Int. 2006 Jan;97(1):29-32 [16336323.001]
  • [Cites] Br J Pharmacol. 2006 Feb;147 Suppl 2:S25-40 [16465182.001]
  • [Cites] BMC Urol. 2006;6:6 [16519806.001]
  • [Cites] Eur Urol. 2006 Nov;50(5):1050-7 [16753252.001]
  • [Cites] J Urol. 2006 Jul;176(1):177-85 [16753396.001]
  • [Cites] Eur Urol. 2006 Dec;50(6):1306-14; discussion 1314-5 [17049716.001]
  • [Cites] Eur Urol. 2007 May;51(5):1350-5; discussion 1355-6 [17070984.001]
  • [Cites] N Engl J Med. 2000 Mar 2;342(9):665 [10702067.001]
  • [Cites] Lab Invest. 2000 Oct;80(10):1491-9 [11045565.001]
  • [Cites] Am J Manag Care. 2000 Jul;6(11 Suppl):S599-606 [11183903.001]
  • [Cites] Lancet. 2001 Aug 4;358(9279):401-3 [11502339.001]
  • [Cites] Neurourol Urodyn. 2002;21(2):167-78 [11857671.001]
  • [Cites] BJU Int. 2000 May;85 Suppl 3:1-6; discussion 8-9 [11954191.001]
  • [Cites] Urology. 2004 Mar;63(3 Suppl 1):24-31 [15013649.001]
  • [Cites] Urol Clin North Am. 2005 Feb;32(1):113-5, viii [15698884.001]
  • [Cites] BJU Int. 2005 Aug;96(3):341-4 [16042727.001]
  • [Cites] J Urol. 2006 Jan;175(1):191-4; discussion 194-5 [16406907.001]
  • [Cites] BJU Int. 2006 Mar;97(3):547-50 [16469023.001]
  • [Cites] J Urol. 2006 Mar;175(3 Pt 1):999-1004; discussion 1004 [16469601.001]
  • [Cites] BJU Int. 2006 Sep;98(3):643-50 [16925766.001]
  • [Cites] Br J Urol. 1991 Nov;68(5):483-6 [1747722.001]
  • [Cites] BJU Int. 2007 Jun;99 Suppl 3:1-7 [17488366.001]
  • [Cites] Urology. 2008 May;71(5):839-43 [18342923.001]
  • [Cites] Br J Urol. 1978 Jun;50(4):243-5 [753469.001]
  • [Cites] Br J Urol. 1995 May;75(5):592-6 [7613795.001]
  • [Cites] Br J Urol. 1994 Jan;73(1):3-8 [8298896.001]
  • [Cites] Br J Urol. 1996 Mar;77(3):333-8 [8814833.001]
  • [Cites] J Urol. 1996 Nov;156(5):1744-7 [8863585.001]
  • [Cites] Scand J Urol Nephrol Suppl. 1996;179:47-53 [8908664.001]
  • [Cites] J Urol. 1997 Dec;158(6):2087-92 [9366318.001]
  • [Cites] Br J Urol. 1998 Jan;81(1):68-72 [9467479.001]
  • [Cites] J Urol. 2000 Feb;163(2):646-51 [10647702.001]
  • [Cites] Br J Pharmacol. 2002 Dec;137(7):1001-10 [12429572.001]
  • [Cites] World J Urol. 2003 May;20(6):327-36 [12811491.001]
  • [Cites] J Urol. 2003 Dec;170(6 Pt 1):2503-7 [14634460.001]
  • [Cites] Eur J Pharmacol. 2004 Jan 12;483(2-3):133-8 [14729100.001]
  • [Cites] Pharmacoeconomics. 2007;25(2):129-42 [17249855.001]
  • [Cites] J Pharmacol Exp Ther. 2007 May;321(2):642-7 [17293563.001]
  • [Cites] BJU Int. 2007 Aug;100(2):419-29 [17617145.001]
  • [Cites] J Pharmacol Exp Ther. 2007 Oct;323(1):202-9 [17626794.001]
  • [Cites] Cochrane Database Syst Rev. 2007;(3):CD005493 [17636801.001]
  • [Cites] Int J Urol. 2007 Jul;14(7):595-7 [17645600.001]
  • [Cites] Neurourol Urodyn. 2008;27(1):13-21 [17671973.001]
  • [Cites] Neurourol Urodyn. 2007 Oct;26(6 Suppl):914-9 [17763395.001]
  • [Cites] Neurourol Urodyn. 2007 Oct;26(6 Suppl):928-33 [17806124.001]
  • [Cites] J Urol. 2007 Nov;178(5):2029-34 [17869298.001]
  • [Cites] J Clin Invest. 2007 Nov;117(11):3453-62 [17948126.001]
  • [Cites] Eur Urol. 2008 Feb;53(2):391-9 [18031925.001]
  • [Cites] Naunyn Schmiedebergs Arch Pharmacol. 2008 Jun;377(4-6):449-62 [18060543.001]
  • [Cites] BJU Int. 2008 Mar;101(5):615-20 [18070178.001]
  • [Cites] Curr Med Res Opin. 2008 Feb;24(2):343-7 [18073008.001]
  • [Cites] Ann R Coll Surg Engl. 2007 Sep;89(6):580-5 [18201471.001]
  • [Cites] Am J Physiol Renal Physiol. 2008 Apr;294(4):F821-9 [18216148.001]
  • [Cites] Eur Urol. 2008 May;53(5):1029-37 [18243515.001]
  • [Cites] Naunyn Schmiedebergs Arch Pharmacol. 2008 Jun;377(4-6):473-81 [18311486.001]
  • [Cites] Eur Urol. 2008 Jun;53(6):1245-53 [18343564.001]
  • [Cites] Pflugers Arch. 2008 Oct;457(1):61-6 [18421472.001]
  • [Cites] BJU Int. 2008 Jun;101(11):1388-95 [18454794.001]
  • [Cites] Nat Clin Pract Urol. 2008 Jun;5(6):319-28 [18461049.001]
  • [Cites] Int J Urol. 2008 Aug;15(8):681-7 [18462357.001]
  • [Cites] Urology. 2008 Nov;72(5):1174-8 [18468662.001]
  • [Cites] J Urol. 2008 Jul;180(1):217-22 [18499184.001]
  • [Cites] Eur Urol. 2009 Jan;55(1):100-19 [18823697.001]
  • [Cites] Curr Urol Rep. 2008 Nov;9(6):445-51 [18947508.001]
  • [Cites] Clin Ther. 2008 Oct;30(10):1766-81 [19014833.001]
  • [Cites] Eur Urol. 2009 Jun;55(6):1440-8 [19054608.001]
  • [Cites] J Urol. 2009 Apr;181(4):1764-72 [19233423.001]
  • [Cites] BJU Int. 2009 Aug;104(3):352-60 [19281467.001]
  • [Cites] Neurourol Urodyn. 2010;29(1):49-55 [19412958.001]
  • [Cites] Neurourol Urodyn. 2010;29(1):82-7 [20025023.001]
  • [Cites] Neurourol Urodyn. 2010;29(1):119-27 [20025025.001]
  • [Cites] Br J Urol. 1995 Nov;76(5):551-7 [8535671.001]
  • [Cites] Cytokine. 1997 Sep;9(9):696-701 [9325019.001]
  • [Cites] Urology. 1997 Dec;50(6A Suppl):36-52; discussion 53-6 [9426749.001]
  • [Cites] Urology. 1997 Dec;50(6A Suppl):57-67; discussion 68-73 [9426752.001]
  • [Cites] World J Urol. 1998;16(4):268-73 [9775426.001]
  • [Cites] Drugs Aging. 2003;20(11):857-64 [12964892.001]
  • (PMID = 21789091.001).
  • [ISSN] 1756-2880
  • [Journal-full-title] Therapeutic advances in urology
  • [ISO-abbreviation] Ther Adv Urol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC3126078
  • [Keywords] NOTNLM ; detrusor overactivity / overactive bladder / urge incontinence / urgency
  •  go-up   go-down


79. Mann S, Johnson MP, Wilson RD: Fetal thoracic and bladder shunts. Semin Fetal Neonatal Med; 2010 Feb;15(1):28-33
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Fetal thoracic and bladder shunts.
  • Congenital obstructive lesions involving the bladder and the lung can lead to serious complications for the newborn.
  • The in-utero placement of a diverting shunt in the fetal bladder or thoracic cavity can decrease the morbidity and mortality associated with these obstructive conditions.
  • This review focuses on the indications for prenatal evaluation, technique, and outcomes for those fetuses with a lower urinary tract obstruction, congenital pleural effusion or macrocystic congenital cystic adenomatoid malformation after placement of a vesicoamniotic or thoracoamniotic shunt.

  • MedlinePlus Health Information. consumer health - Fetal Health and Development.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2009. Published by Elsevier Ltd.
  • (PMID = 19596218.001).
  • [ISSN] 1878-0946
  • [Journal-full-title] Seminars in fetal & neonatal medicine
  • [ISO-abbreviation] Semin Fetal Neonatal Med
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Netherlands
  • [Number-of-references] 38
  •  go-up   go-down


80. Thwaini A, McLeod A, Nambirajan T: Laparoscopic bladder diverticulectomy. J Laparoendosc Adv Surg Tech A; 2008 Dec;18(6):849-51
MedlinePlus Health Information. consumer health - Bladder Diseases.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Laparoscopic bladder diverticulectomy.
  • Acquired bladder diverticulae are herniations of the bladder mucosa through detrusor muscle.
  • Due to the ineffective emptying of the bladder diverticulum, urine accumulation may lead to urinary tract infection, stone disease, and lower urinary tract malignancy in the diverticulum.
  • We report a case of laparoscopic bladder diverticulectomy for transitional cell carcinoma in an acquired bladder diverticulum.
  • To our knowledge, this is the third case of laparoscopic diverticulectomy for a tumor.
  • [MeSH-major] Carcinoma, Transitional Cell / surgery. Diverticulum / surgery. Laparoscopy / methods. Urinary Bladder Diseases / surgery. Urinary Bladder Neoplasms / surgery

  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19105670.001).
  • [ISSN] 1092-6429
  • [Journal-full-title] Journal of laparoendoscopic & advanced surgical techniques. Part A
  • [ISO-abbreviation] J Laparoendosc Adv Surg Tech A
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


81. Katz DJ, Sengupta S, Snow RM: Isolated vasculitis of the bladder. Urology; 2005 Apr;65(4):797
MedlinePlus Health Information. consumer health - Vasculitis.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Isolated vasculitis of the bladder.
  • We describe a case of isolated vasculitis involving the bladder that presented with severe irritative voiding and hematuria.
  • It is important to differentiate this rare pathologic entity from the much more frequent tumors of the bladder because the treatment is medical rather than surgical.
  • [MeSH-major] Urinary Bladder / blood supply. Urinary Bladder Diseases / diagnosis. Vasculitis / diagnosis

  • Genetic Alliance. consumer health - Vasculitis.
  • MedlinePlus Health Information. consumer health - Bladder Diseases.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15833535.001).
  • [ISSN] 1527-9995
  • [Journal-full-title] Urology
  • [ISO-abbreviation] Urology
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


82. Rioja Zuazu J, Toutziaris V, Laguna Pes MP, de Reijke TM, de la Rosette JJ: [Laser and bladder tumors]. Arch Esp Urol; 2008 Nov;61(9):994-1003
MedlinePlus Health Information. consumer health - Bladder Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Laser and bladder tumors].
  • Bladder cancer is one of the most frequents pathologies in urology.
  • We perform a review and try to assess the actual indications for its employment in the treatment of bladder cancer, as well as future applications.
  • [MeSH-major] Laser Therapy. Urinary Bladder Neoplasms / surgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19140580.001).
  • [ISSN] 0004-0614
  • [Journal-full-title] Archivos españoles de urología
  • [ISO-abbreviation] Arch. Esp. Urol.
  • [Language] spa
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Spain
  • [Number-of-references] 44
  •  go-up   go-down


83. Karam JA, Kabbani W, Sagalowsky AI: Pseudosarcomatous fibromyxoid tumor of the bladder. Urol Oncol; 2008 May-Jun;26(3):291-4
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pseudosarcomatous fibromyxoid tumor of the bladder.
  • Pseudosarcomatous fibromyxoid tumors are uncommon lesions with uncertain pathogenesis.
  • Work-up revealed a bladder mass that was initially treated with transurethral resection that showed pseudosarcomatous fibromyxoid tumors.
  • Partial cystectomy is a viable option in the treatment of recurrent symptomatic pseudosarcomatous fibromyxoid tumors of the bladder, when performed selectively.
  • [MeSH-major] Fibroma / pathology. Sarcoma / pathology. Urinary Bladder Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18452822.001).
  • [ISSN] 1078-1439
  • [Journal-full-title] Urologic oncology
  • [ISO-abbreviation] Urol. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


84. Lopes EJ, dos Santos TC, Martins V: [Schistosomiasis mansoni simulating bladder neoplasia]. Rev Soc Bras Med Trop; 2006 May-Jun;39(3):287-8
Hazardous Substances Data Bank. OXAMNIQUINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Schistosomiasis mansoni simulating bladder neoplasia].
  • [Transliterated title] Esquistossomose mansônica simulando neoplasia da bexiga.
  • Cytoscopy showed a protuberant tumor in the bladder anterior wall, suggestive of cancer.
  • Transurethral resection confirmed the diagnosis.
  • The case presented in this work emphasizes that not all the tumors of bladder with microscopic hematuria are bladder cancers.
  • [MeSH-major] Oxamniquine / therapeutic use. Schistosoma mansoni / isolation & purification. Schistosomiasis mansoni / diagnosis. Schistosomicides / therapeutic use. Urinary Bladder Diseases / parasitology
  • [MeSH-minor] Adult. Animals. Biopsy. Diagnosis, Differential. Humans. Male. Treatment Outcome. Urinary Bladder Neoplasms / diagnosis

  • Genetic Alliance. consumer health - Schistosomiasis.
  • MedlinePlus Health Information. consumer health - Bladder Diseases.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16906256.001).
  • [ISSN] 0037-8682
  • [Journal-full-title] Revista da Sociedade Brasileira de Medicina Tropical
  • [ISO-abbreviation] Rev. Soc. Bras. Med. Trop.
  • [Language] por
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Brazil
  • [Chemical-registry-number] 0 / Schistosomicides; 0O977R722D / Oxamniquine
  •  go-up   go-down


85. Oliveira PA, Colaco A, De la Cruz P LF, Lopes C: Experimental bladder carcinogenesis-rodent models. Exp Oncol; 2006 Mar;28(1):2-11
MedlinePlus Health Information. consumer health - Bladder Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Experimental bladder carcinogenesis-rodent models.
  • Several rodent models of bladder cancer development have been established.
  • The aim of this review article is to provide a critical assessment of different animal models available for the study of bladder carcinogenesis, its chemoprevention and therapy.
  • Spontaneous bladder tumor models are extremely rare.
  • We describe chemical carcinogens most commonly used to induce bladder cancer, pellet implantation and urinary calculi, agents that promote bladder cancer, and irradiation.
  • We also evaluated other tools such as cell cultures, tumor implantation and transgenic models for bladder cancer, that have been developed to study the process.
  • The review considers how several imaging techniques can be applied to study rodent bladder carcinogenesis.
  • [MeSH-major] Neoplasms, Experimental. Urinary Bladder Neoplasms / pathology
  • [MeSH-minor] Animals. Animals, Genetically Modified. Carcinogens. Disease Models, Animal. Genetic Engineering. Humans. Neoplasm Transplantation / methods. Rodentia

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16614700.001).
  • [ISSN] 1812-9269
  • [Journal-full-title] Experimental oncology
  • [ISO-abbreviation] Exp. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] Ukraine
  • [Chemical-registry-number] 0 / Carcinogens
  • [Number-of-references] 99
  •  go-up   go-down


86. Wilkinson K: Supplementary prescribing for overactive bladder. Nurs Stand; 2005 Jan 19-25;19(19):38-42
MedlinePlus Health Information. consumer health - Urinary Incontinence.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Supplementary prescribing for overactive bladder.
  • Overactive bladder is a common condition that can be treated effectively in primary care by nurses.
  • Supplementary nurse prescribing enables nurses with the appropriate qualification to provide holistic programmes of care for individuals with an overactive bladder.
  • [MeSH-major] Community Health Nursing / organization & administration. Drug Prescriptions. Nurse Clinicians / organization & administration. Primary Health Care / organization & administration. Professional Autonomy. Urinary Incontinence / drug therapy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15700865.001).
  • [ISSN] 0029-6570
  • [Journal-full-title] Nursing standard (Royal College of Nursing (Great Britain) : 1987)
  • [ISO-abbreviation] Nurs Stand
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Number-of-references] 27
  •  go-up   go-down


87. Sithasanan N, Kihne M, Naidu RR, Ramanujam TM: Twisted fate of bladder catheters. Med J Malaysia; 2006 Aug;61(3):369-70

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Twisted fate of bladder catheters.
  • Catheter knotting is a rare complication of bladder catheterisation.
  • We report a case of a vesical calculus formed over a broken and retained supra-pubic catheter which to the best of our knowledge has yet to be reported, along with three other cases of bladder catheter knotting.
  • [MeSH-major] Urinary Catheterization / instrumentation
  • [MeSH-minor] Adolescent. Child. Equipment Failure. Humans. Infant, Newborn. Male. Urinary Calculi / etiology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17240594.001).
  • [ISSN] 0300-5283
  • [Journal-full-title] The Medical journal of Malaysia
  • [ISO-abbreviation] Med. J. Malaysia
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Malaysia
  •  go-up   go-down


88. Rigby D: Underactive bladder syndrome. Nurs Stand; 2005 May 11-17;19(35):57-64; quiz 66-7
MedlinePlus Health Information. consumer health - Bladder Diseases.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Underactive bladder syndrome.
  • Underactive bladder syndrome causes difficulty in voiding, resulting in incomplete bladder emptying.
  • [MeSH-major] Urinary Bladder Diseases / diagnosis. Urinary Bladder Diseases / therapy
  • [MeSH-minor] Clinical Protocols. Diagnosis, Differential. Female. Humans. Male. Quality of Life. Urinary Bladder / physiopathology. Urinary Catheterization / instrumentation. Urinary Catheterization / methods. Urinary Catheterization / nursing. Urine

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15915959.001).
  • [ISSN] 0029-6570
  • [Journal-full-title] Nursing standard (Royal College of Nursing (Great Britain) : 1987)
  • [ISO-abbreviation] Nurs Stand
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Number-of-references] 38
  •  go-up   go-down


89. Nordling J: Sensory bladder disorders. Int J Clin Pract Suppl; 2006 Dec;(151):38-42
MedlinePlus Health Information. consumer health - Interstitial Cystitis.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Sensory bladder disorders.
  • Sensory bladder disorders include disorders involving abnormal sensations resulting from many diseases of the urinary bladder.
  • In a proportion of patients no cause can be found and if pain or pelvic pressure is a part of the symptomatology, they are labelled as having painful bladder syndrome (PBS).
  • In a subgroup of these patients abnormal findings can be demonstrated at cystoscopy and/or by histological examination of bladder biopsies.
  • This paper looks into the differential diagnosis, evaluation and treatment of patients with PBS.
  • [MeSH-major] Cystitis, Interstitial / diagnosis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17169010.001).
  • [ISSN] 1368-504X
  • [Journal-full-title] International journal of clinical practice. Supplement
  • [ISO-abbreviation] Int J Clin Pract Suppl
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Number-of-references] 43
  •  go-up   go-down


90. Castillo O, Hoyos J, Vitagliano G, Arellano L: [Inverted papilloma of the bladder]. Arch Esp Urol; 2006 Sep;59(7):691-5
MedlinePlus Health Information. consumer health - Bladder Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Inverted papilloma of the bladder].
  • [Transliterated title] Papiloma invertido vesical.
  • OBJECTIVES: To report a series of patients with bladder inverted papilloma, pointing out the clinical features, presentations, treatment options and outcomes.
  • METHODS: We reviewed the medical charts of all patients with the diagnosis of bladder inverted papilloma treated by our group between July 1996 and June 2003.
  • RESULTS: 16 cases of inverted papilloma of the bladder were diagnosed in ten males and six females, with a mean age of 53.1 yr. (range 31-72).
  • In 14/16 patients the lesion was localized in the bladder trigone.
  • [MeSH-major] Papilloma, Inverted. Urinary Bladder Neoplasms

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17078392.001).
  • [ISSN] 0004-0614
  • [Journal-full-title] Archivos españoles de urología
  • [ISO-abbreviation] Arch. Esp. Urol.
  • [Language] spa
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Spain
  • [Number-of-references] 12
  •  go-up   go-down


91. Crook TJ, Mead Z, Vadgama B, Malone PS: A case series of nephrogenic adenoma of the urethra and bladder in children: review of this rare diagnosis, its natural history and management, with reference to the literature. J Pediatr Urol; 2006 Aug;2(4):323-8

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A case series of nephrogenic adenoma of the urethra and bladder in children: review of this rare diagnosis, its natural history and management, with reference to the literature.
  • Nephrogenic adenoma (NA) is a rare benign tumour of the urinary tract and is found most commonly in the bladder.
  • Here are presented four cases of paediatric NA, two bladder and two urethral.
  • Their diagnostic and management features in the context of differential diagnosis and natural history are discussed.
  • A 3-year-old girl presented with recurrent urinary tract infections (UTIs) and haematuria.
  • An ultrasound scan suggested a large bladder tumour, which was biopsied cystoscopically, and histology confirmed an NA.
  • She then underwent open resection of the tumour.
  • A cystoscopy showed a papillary tumour, which was confirmed as NA on histology.
  • In the two bladder cases, but not the urethral cases, a causative factor could be identified.
  • Recurrence was noted in both of the bladder cases.
  • Treatment consisted of endoscopic and open ablation of the tumours, and endoscopic fulguration of recurrences for the bladder cases, and surveillance for the urethral cases.
  • Only two previous cases of urethral and 25 cases of bladder NA have been reported in children.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18947630.001).
  • [ISSN] 1873-4898
  • [Journal-full-title] Journal of pediatric urology
  • [ISO-abbreviation] J Pediatr Urol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


92. Yiee J, Wilcox D: Abnormalities of the fetal bladder. Semin Fetal Neonatal Med; 2008 Jun;13(3):164-70

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Abnormalities of the fetal bladder.
  • This review aims to outline the management of a fetus in whom a distended bladder or an absent bladder has been identified during prenatal fetal screening.
  • [MeSH-major] Fetus / abnormalities. Ureterocele / therapy. Urethra / abnormalities. Urinary Bladder / abnormalities
  • [MeSH-minor] Bladder Exstrophy. Cloaca / abnormalities. Female. Humans. Pregnancy. Prune Belly Syndrome / diagnosis. Syndrome. Ultrasonography, Prenatal

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18053783.001).
  • [ISSN] 1744-165X
  • [Journal-full-title] Seminars in fetal & neonatal medicine
  • [ISO-abbreviation] Semin Fetal Neonatal Med
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Netherlands
  • [Number-of-references] 46
  •  go-up   go-down


93. Tran H, Nguyen N, Nguyen T: Neonatal bladder rupture. Indian J Pediatr; 2009 Apr;76(4):427-9
MedlinePlus Health Information. consumer health - Bladder Diseases.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Neonatal bladder rupture.
  • Neonatal bladder rupture is rare as a complication of bladder obstruction due to abnormal anatomy or iatrogenic cause such as umbilical catheterization.
  • The present study describes the case of a 27-day old infant with ascites due to bladder perforation secondary to bladder wall necrosis as a result of severe urinary tract infection.
  • [MeSH-major] Urinary Bladder Diseases / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19205633.001).
  • [ISSN] 0973-7693
  • [Journal-full-title] Indian journal of pediatrics
  • [ISO-abbreviation] Indian J Pediatr
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] India
  •  go-up   go-down


94. Spiess PE, Tuziak T, Tibbs RF, Bassett R, Tamboli P, Brown GA, Grossman HB, Ayala AG, Czerniak B: Pseudosarcomatous and sarcomatous proliferations of the bladder. Hum Pathol; 2007 May;38(5):753-61
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pseudosarcomatous and sarcomatous proliferations of the bladder.
  • Pseudosarcomatous fibromyxoid tumor (PFT), postoperative spindle cell nodule (PSN), sarcoma, and sarcomatoid carcinoma of the bladder are frequently difficult to distinguish histopathologically with significant differences in disease-related outcomes.
  • A retrospective review of our pathology registry over the last 25 years identified 7 PFT, 10 PSN, 18 primary bladder sarcomas, and 17 sarcomatoid carcinomas.
  • A previous history of urological instrumentation and bladder cancer was present in all patients with PSN but none of the patients with PFT.
  • Pseudosarcomatous fibromyxoid tumors were characterized by a tissue culture-like proliferation of myofibroblastic cells with focal atypia and overall cytoarchitectural features mimicking nodular fasciitis.
  • Pseudosarcomatous fibromyxoid tumor and PSN have unique clinical and pathologic features that allow their distinction from primary bladder sarcoma and sarcomatoid carcinoma.
  • [MeSH-major] Sarcoma / pathology. Urinary Bladder Neoplasms / pathology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Carcinoma / pathology. Female. Fibroma / pathology. Humans. Male. Middle Aged. Neoplasm Metastasis. Retrospective Studies

  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17306332.001).
  • [ISSN] 0046-8177
  • [Journal-full-title] Human pathology
  • [ISO-abbreviation] Hum. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


95. Brand K, Littlejohn G, Kristjanson L, Wisniewski S, Hassard T: The fibromyalgia bladder index. Clin Rheumatol; 2007 Dec;26(12):2097-103
MedlinePlus Health Information. consumer health - Interstitial Cystitis.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The fibromyalgia bladder index.
  • The aim of this study was to determine whether an existing outcome measure, the Interstitial Cystitis Symptom and Problem Index (ICSI/ICPI), is a valid, reliable, and clinically relevant instrument to assess the sensory urinary symptoms in women with fibromyalgia syndrome (FM).
  • Ninety women with American College of Rheumatology 90 FM and who had at least two sensory bladder symptoms participated in the study.
  • All underwent urological screening to exclude lower urinary tract pathology.
  • The eight items of the index configured differently and formed two subscales of a newly developed Fibromyalgia Bladder Index.
  • The two subscales of this index include the Bladder Urgency and Pain Subscale and the Bladder Frequency and Nocturia Subscale.
  • This index has high internal consistency reliability (Cronbach's alpha coefficient of 0.81), test-retest reliability showing intraclass correlation of 0.85, and high concurrent validity through correlations between the Fibromyalgia Bladder Index and the KHQ (0.735, p = 0.000) and the FIQ (0.433, p = 0.000).
  • This more specific configuration of the ICSI/ICPI better reflects FM bladder symptomatology.
  • The Fibromyalgia Bladder Index is a validated FM-specific instrument that captures information about the sensory bladder symptoms and their impact in this fibromyalgia population.
  • [MeSH-major] Cystitis, Interstitial / etiology. Fibromyalgia / complications. Urinary Bladder / physiopathology

  • Genetic Alliance. consumer health - Fibromyalgia.
  • MedlinePlus Health Information. consumer health - Fibromyalgia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17476564.001).
  • [ISSN] 0770-3198
  • [Journal-full-title] Clinical rheumatology
  • [ISO-abbreviation] Clin. Rheumatol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Belgium
  •  go-up   go-down


96. Sakellaris G, Cervellione RM, Dickson AP: An unusual bladder/cloacal exstrophy with urachal exstrophy. Urol Int; 2008;81(1):113-5
Genetic Alliance. consumer health - Exstrophy of the Bladder.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] An unusual bladder/cloacal exstrophy with urachal exstrophy.
  • The authors report a previously unpublished association of bladder exstrophy with cleft lip, exomphalos, Meckel's diverticulum imperforate anus, and a large urachal mass protruding below the umbilicus.
  • None of the theories formulated to explain the embryogenesis of bladder exstrophy can explain these findings.
  • The abnormality is within the bladder exstrophy/cloacal exstrophy spectrum.
  • [MeSH-major] Bladder Exstrophy / diagnosis. Cloaca / physiopathology. Urachus / physiopathology
  • [MeSH-minor] Abnormalities, Multiple. Anus, Imperforate / complications. Anus, Imperforate / diagnosis. Humans. Infant, Newborn. Male. Urinary Bladder / pathology

  • Genetic Alliance. consumer health - Cloacal Exstrophy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2008 S. Karger AG, Basel.
  • (PMID = 18645282.001).
  • [ISSN] 1423-0399
  • [Journal-full-title] Urologia internationalis
  • [ISO-abbreviation] Urol. Int.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Switzerland
  •  go-up   go-down


97. Horiuchi K, Shimizu H, Yoshida K, Nishimura T: New ultrasonic cystofiberscope for staging bladder tumors. J Endourol; 2005 Mar;19(2):130-2
MedlinePlus Health Information. consumer health - Bladder Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] New ultrasonic cystofiberscope for staging bladder tumors.
  • We report on a new ultrasonic cystofiberscope for staging bladder tumors.
  • The endoscope makes it possible to view endoscopic and ultrasound images of bladder tumors at any location, either alternately in full screen or simultaneously on the same monitor, with higher resolution.
  • The cystofiberscope is useful for assessing the depth of bladder tumor invasion accurately.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15798403.001).
  • [ISSN] 0892-7790
  • [Journal-full-title] Journal of endourology
  • [ISO-abbreviation] J. Endourol.
  • [Language] ENG
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


98. Kajbafzadeh AM, Saeedi P, Sina AR, Payabvash S, Salmasi AH: Infantile bladder rupture during voiding cystourethrography. Int Braz J Urol; 2007 Jul-Aug;33(4):532-5; discussion 535
MedlinePlus Health Information. consumer health - Bladder Diseases.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Infantile bladder rupture during voiding cystourethrography.
  • Bladder rupture is rare during infancy and most of reported cases had urethral obstruction or neurogenic bladder.
  • We report two cases of infantile bladder rupture during voiding cystourethrography (VCUG).
  • Consideration of expected bladder volume for body weight, and close monitoring of bladder pressure and injection speed could prevent such complications.
  • [MeSH-major] Iatrogenic Disease. Urinary Bladder / injuries. Urinary Bladder Diseases / etiology. Urography / adverse effects

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17767759.001).
  • [ISSN] 1677-5538
  • [Journal-full-title] International braz j urol : official journal of the Brazilian Society of Urology
  • [ISO-abbreviation] Int Braz J Urol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Brazil
  • [Chemical-registry-number] 0 / Contrast Media
  •  go-up   go-down


99. Zhang J, Gerst S, Lefkowitz RA, Bach A: Imaging of bladder cancer. Radiol Clin North Am; 2007 Jan;45(1):183-205
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Imaging of bladder cancer.
  • Bladder cancer is a heterogeneous and frequently multifocal disease with a variable clinical course.
  • The management of bladder cancer is therefore challenging and complicated.
  • CT and MR imaging have replaced the traditional excretory urography and are emerging as the imaging modalities of choice for work-up of patients who have bladder cancer.
  • Imaging provides essential diagnostic information for detection, staging, and post-treatment follow-up of bladder cancer.
  • [MeSH-major] Magnetic Resonance Imaging. Positron-Emission Tomography. Tomography, X-Ray Computed. Ultrasonography. Urinary Bladder Neoplasms / diagnosis. Urography
  • [MeSH-minor] Adult. Age Factors. Aged. Aged, 80 and over. Cystectomy. Cystoscopy. Cystostomy. Diagnosis, Differential. Female. Follow-Up Studies. Humans. Lymphatic Metastasis / diagnosis. Male. Middle Aged. Neoplasm Metastasis / diagnosis. Neoplasm Recurrence, Local / diagnosis. Neoplasm Staging. Prognosis. Time Factors. Treatment Outcome. Ultrasonography, Doppler. Urinary Bladder / pathology


100. Neeli S, Prabha V, Alur S, Malur P: Penile metastasis from primay mucinous adenocarcinoma of bladder. Indian J Urol; 2007 Jul;23(3):314-6

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Penile metastasis from primay mucinous adenocarcinoma of bladder.
  • Primary adenocarcinoma of the urinary bladder is not common.
  • Though penile metastases from transitional cell carcinoma are reported, such metastases from adenocarcinoma of urinary bladder is unknown.
  • We report a 55-year-old male having penile metastasis from primary mucinous adenocarcinoma of bladder.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Br J Urol. 1998 Aug;82(2):206-12 [9722755.001]
  • [Cites] Cancer. 1991 Apr 15;67(8):2165-72 [1706216.001]
  • [Cites] J Urol. 1990 Apr;143(4):671-8 [2179579.001]
  • [Cites] Br J Urol. 1971 Feb;43(1):4-15 [4926456.001]
  • [Cites] J Urol. 1964 May;91:538-48 [14154540.001]
  • [Cites] J Androl. 2003 Jul-Aug;24(4):499-500 [12826689.001]
  • [Cites] Urol Oncol. 2006 Jan-Feb;24(1):13-20 [16414487.001]
  • [Cites] Cancer. 1956 May-Jun;9(3):626-32 [13330017.001]
  • [Cites] Urology. 2003 Jul;62(1):145 [12837452.001]
  • (PMID = 19718338.001).
  • [ISSN] 0970-1591
  • [Journal-full-title] Indian journal of urology : IJU : journal of the Urological Society of India
  • [ISO-abbreviation] Indian J Urol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] India
  • [Other-IDs] NLM/ PMC2721614
  • [Keywords] NOTNLM ; Adenocarcinoma / penile metastasis / urinary bladder neoplasm
  •  go-up   go-down






Advertisement